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ABSTRACT 
 
Angiotensin II (Ang II) plays a very important role in regulating cardiac and vascular 
contraction and proliferation/hypertrophy via stimulation of AT1 receptors. A few studies 
have demonstrated that 5-lipoxygenase (5-LO) derived cysteinyl leukotrienes (CysLT) 
contribute to Ang II evoked tension responses in rat aortic rings.  Whether CysLT would 
contribute to Ang II evoked Ca2+ mobilization in neonatal rat cardiomyocytes (NRC) and 
rat aortic smooth muscle cells (ASMC) has not been investigated.  In the present study, 
using primary cultures of NRC and minimally passaged cultures of rat ASMC, an effort 
was made to address this key issue.  The agonists evoked increase in cytosolic free 
calcium ([Ca2+]i) level was determined by fura-2 fluorescence measurement in NRC and 
ASMC.  Total CysLT levels in the culture medium were determined using an ELISA kit. 
CysLT1/CysLT2 receptor mRNA levels of NRC and ASMC were quantified by Northern 
blot analysis.  In NRC, the AT1 but not the AT2 selective antagonist, attenuated the 
elevations in [Ca2+]i and CysLT levels evoked by Ang II.  Vasopressin (AVP) and 
endothelin-1 (ET-1) increased [Ca2+]i but not CysLT levels.  The 5-LO inhibitor, 
AA861, and the CysLT1 selective antagonist, MK-571, reduced the maximal [Ca
2+]i 
responses (Emax)  to Ang II but not to AVP and ET-1.  While CysLT1 antagonist reduced 
the Emax to leukotriene D4, (LTD4), the dual CysLT1/CysLT2 antagonist, BAY u9773, 
completely blocked the [Ca2+]i elevation to both LTD4 and leukotriene C4 (LTC4).  Both 
CysLT1 and CysLT2 mRNA were detected in NRC.  The inositol 1,4,5 triphosphate 
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(InsP3) antagonist, 2-aminoethoxyphenyl borate (2-APB), attenuated the [Ca
2+]i 
responses to Ang II and LTD4.  In ASMC, Ang II, ET-1 and AVP evoked [Ca
2+]i 
responses were significantly higher in the cultured ASMC isolated from spontaneously 
hypertensive rats (SHR) compared to ASMC derived from age-matched normotensive 
Wistar-Kyoto (WKY) strain.  Addition of either MK571 or BAY u9773, reduced the 
Emax values to Ang II (but not to ET-1and AVP) in both strains.  While BAY u9773 
abolished the [Ca2+]i responses evoked by both LTD4 and LTC4, MK571, the CysLT1 
antagonist reduced the responses evoked by LTD4 but not LTC4.  The basal CysLT 
levels were higher in the ASMC of SHR.  Ang II but not ET-1 and AVP evoked time and 
concentration dependent increases in CysLT levels in ASMC of both WKY and SHR 
strains.  The AT1 selective antagonist, losartan, but not the AT2 antagonist, PD123319, 
attenuated the increases in [Ca2+]i and CysLT levels evoked by Ang II.  The InsP3 
antagonist, attenuated the [Ca2+]i responses to Ang II, LTD4 and LTC4.  Both CysLT1 
and CysLT2 mRNA were detected in the ASMC of either strain; but they were 
significantly higher in SHR.  These data suggest that AT1 mediated CysLT production 
contributes to Ang II evoked Ca2+ mobilization in NRC and that elevated CysLT 
production along with increased expression of both CysLT1/CysLT2 receptors may 
account for the exaggerated [Ca2+]i responses to Ang II in ASMC of SHR due to 
enhanced mobilization of Ca2+ from InsP3 sensitive intracellular Ca
2+ stores. 
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1.   INTRODUCTION 
 
1.1 The Role of Renin Angiotensin System (RAS) in the 
Regulation of Cardiovascular function 
1.1.1 Generation of Angiotensin II (Ang II) 
Ang II plays multiple roles in the regulation of cardiovascular function (Touyz et al, 
2000).  As an octapeptide hormone, Ang II is the key component of the RAS.  It regulates 
plasma volume, blood pressure, sympathetic nervous system activity, and thirst 
responses. In addition, Ang II also plays an important role in pathological adaptation, 
such as myocardial remodeling after myocardial infarction and vascular remodeling in 
hypertension.  The RAS was originally considered as a component of the circulating 
system.  However, later studies have also demonstrated that many of its components are 
localized in vascular tissues suggesting the existence of a local tissue RAS (Dzau, 1989; 
Danser, 1996).  Thus Ang II can also be generated locally via tissue RAS.  In the classical 
RAS, the circulating renal-derived renin cleaves the hepatic-derived angiotensinogen at 
the N terminus to generate the decapeptide, angiotensin I. This is subsequently converted 
in the lungs by the dipeptidyl carboxypeptidase, angiotensin-converting enzyme (ACE) to 
the active Ang II (Skeggs et al., 1967; Dorer et al., 1972; Phillips et al., 1993). In 
addition, Ang I can also be converted into the heptapeptide Ang (1-7) by three tissue 
endopeptidases, neutral endopeptidase (NEP) 24.11, NEP 24.15, and NEP 24.26 (Ferrario 
et al., 1997).  Ang II is metabolized by aminopeptidases to Ang III and Ang IV. 
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ACE is ubiquitous in distribution as it is present in the cells, plasma as well as in the 
interstitium. Tissue ACE exists in all major organs including heart, blood vessels, 
adrenals, kidney, liver, brain, and reproductive organs (Hollenberg, 1998), and it has been 
shown to be functional in utero (Schutz et al., 1996; Esther et al., 1997). It has been 
demonstrated that tissue ACE activity reaches the maximum level during the phase of 
major organ development and gradually decreases thereafter (Esther et al., 1997). Except 
renin, all other components of the RAS are generated in the cardiovascular system. ACE 
is observed in high concentrations in vascular adventitia, in cultured vascular smooth 
muscle cells (VSMC) and in endothelial cells (EC; Dzau, 1989; Ekker et al., 1989; 
Naftilan, 1994). Angiotensinogen mRNA and protein have been found in cardiac 
myocytes, vascular smooth muscle (VSM), endothelium, and perivascular fat (Naftilan et 
al., 1991; Naftilan, 1994; Morgan et al., 1996).  As renin is absent in cardiovascular 
system, local generation of Ang II in the interstitium is controlled by tissue ACE since it 
is probably dependent on circulating renin.  Although the function of tissue ACE 
currently remains unknown, it may play a very important role in the regulation of 
regional blood flow as demonstrated in the human forearm, where in situ generated Ang 
II plays a larger role in promoting vasoconstriction than circulating Ang II (Saris et al., 
2000). 
 
Ang II also can be generated via non-ACE pathways, and this may have major 
implications in cardiovascular disease states.  Studies have shown that chymotrypsin-like 
serine protease (chymase) may be an important pathway for the conversion of Ang I to 
Ang II in the human heart (Urata et al., 1990 & 1996) and kidney (Hollenberg, 1998).  
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Functional chymase and a non-ACE pathway have also been observed in vascular tissue 
(Hollenberg et al., 1998; Takai et al., 1998) as well as in the carotid artery (Shiota et al., 
1999). 
 
1.1.2 Angiotensin Receptors 
The diversity of specific physiological effects evoked by Ang II suggested the existence 
of multiple type of Ang II receptors (Peach, 1981; Douglas, 1987). The existence of 
multiple subtypes of Ang II receptors was first confirmed by a pharmacological approach 
using various specific Ang II receptor antagonists (Chiu et al., 1989). In mammalian 
cells, Ang II mediates its effects via at least two high-affinity, G-protein coupled plasma 
membrane receptors, namely AT1 and AT2. Both receptor subtypes have been cloned and 
pharmacologically characterized (Murphy et al., 1991; Sasaki et al., 1991; Kambayashi et 
al., 1993; Mukoyama et al., 1993). Two other Ang II receptors have been termed, AT3 
and AT4 subtypes.  Since the pharmacology of AT3 and AT4 receptors has not been fully 
characterized, these receptors are not yet included in a definitive classification of 
mammalian AT receptors as defined by the International Union of Pharmacology 
Nomenclature Subcommittee for Angiotensin Receptors (de Gasparo, 1995). 
 
 A decade ago, the AT1 receptor was successfully cloned (Murphy et al., 1991; Sasaki et 
al., 1991).  Studies have demonstrated that AT1 receptor belongs to the seven membrane-
spanning G protein-coupled receptor family and typically activates phospholipase C 
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(PLC) via the heterotrimeric Gq protein coupling (de Gasparo et al., 1995; Inagami, 
1995). The human AT1 receptor gene is located on chromosome 3. The AT1 receptor is 
ubiquitously and abundantly presented in adult tissues, including blood vessel, heart, 
kidney, adrenal gland, liver, brain, and lung.  In the vasculature, AT1 receptors are 
expressed at high levels in smooth muscle cells and relatively low levels in the adventitia 
and endothelium (Zhuo et al., 1998; Allen et al., 2000).  AT1 receptor mediates all the 
classical well known physiological actions of Ang II, such as elevation of blood pressure, 
vasoconstriction, increase in cardiac contractility, aldosterone release from the adrenal 
gland, facilitation of catecholamine release from nerve endings, renal sodium and water 
absorption (Timmermans et al., 1993).  This subtype is predominant in the control of Ang 
II-induced cardiovascular functions (Sadoshima, 1998).  In addition, recent accumulating 
evidence supports the notion that by AT1 receptor mediated Ang II may contribute 
directly to the pathogenesis of various cardiovascular and renal diseases (Kim and Iwao, 
2000).  In rodents, two AT1 receptor subtypes have been identified, namely AT1A and 
AT1B, which have 94% homology with regard to amino acid sequence and have similar 
pharmacological properties and tissue distribution patterns (Iwai and Inagami, 1992; Kim 
and Iwao, 2000).  AT1A and AT1B receptor genes in rats are located in chromosome 17 
and 2, respectively.  Studies have revealed that AT1A is the dominant subtype expressed 
in the liver, kidney, vasculature, lung, ovary, and heart, whereas AT1B is expressed in 
greater quantities in the adrenal, anterior pituitary, and uterus (Sandberg et al., 1992; 
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Kakar et al., 1992; Curnow et al., 1992; Iwai and Inagami, 1992). The expression of these 
receptors in the brain varies from region to region.  The AT1 receptor is a glycoprotein 
and consists of 359 amino acids (Sandberg, 1994).  It contains extracellular glycosylation 
sites at the amino terminus (Asn4) and the second extracellular loop (Asp176 and 
Asn188) (Desarnaud et al., 1993). The transmembrane domain at the amino-terminal 
extension and segments in the first and third intracellular loops are responsible for G 
protein interactions with the receptor (Hjorth et al., 1994).  Internalization of G protein-
coupled receptors involves receptor phosphorylation, which may be partially mediated by 
caveola (Berk and Corson, 1997; Ishizaka et al., 1998). Though G protein-coupled 
receptors do not have intrinsic kinase activity, they are phosphorylated on serine and 
threonine residues by the G protein receptor kinase (GRK) family members.  AT1 
receptors are phosphorylated both in the basal state and in response to Ang II stimulation 
(Kai et al., 1994).   Threonine and serine residues between Thr332 and Ser338 of the 
cytoplasmic tail are fundamental for receptor internalization (Hunyady et al., 1994). In 
addition, the AT1 receptor is also phosphorylated at tyrosine residues. Possible tyrosine 
phosphorylation sites within the AT1 receptor include amino acids 302, 312, 319, and 
339 within the carboxyl terminus (Berk and Corson, 1997).  Tyrosine at position 319 is 
very important as it is part of the motif Tyr-Ile-Pro-Pro, which is analogous to a Src 
homology 2 (SH2) binding motif in the PDGF receptor (Tyr-Ile-Pro) and in the epidermal 
growth factor (EGF) receptor (Tyr-Leu-Pro-Pro) (Fantl et al., 1993).  In EGF and PDGF 
receptors, these motifs are target sequences for tyrosine phosphorylation. Various 
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tyrosine kinases, including Src family kinases, Janus kinases (JAK and TYK), and focal 
adhesion kinase (FAK) can phosphorylate tyrosine residues on AT1 receptors. 
 
The other major isoform of Ang II receptor is AT2 subtype. The AT2 receptor gene is 
localized as a single copy on the X chromosome.  Distribution of AT2 binding sites was 
studied using autohistoradiography of nonspecific radioactive Ang II ligands followed by 
displacement with specific antagonists. AT2 is usually ubiquitously expressed in fetal 
tissues and declines rapidly after birth, suggesting a possible role of this receptor in fetal 
development and organ morphogenesis (Nahmias and Strosberg, 1995). In adults, AT2 
receptor expression is detectable in the heart, pancreas, kidney, brain, adrenals, and 
vasculature (Viswanathan and Saavedra, 1994; Touyz et al., 1999a). In the vasculature, 
AT2 receptors predominate in the adventitia tissue and are detectable in the media (Zhuo 
et al., 1998). AT2 receptors are also expressed in several cell lines (Inagami, 1995). 
Unlike the AT1 receptor, there is no evidence for subtypes of the AT2 receptor.  The AT2 
receptor is also a seven transmembrane domain.  It is a Gi protein-coupled receptor, 
comprising 363 amino acids.  It has low amino acid sequence homology (~32%) with 
AT1A or AT1B receptors (Mukoyama et al., 1993). Although the exact signaling 
pathways recruited by AT2 receptor activation and its functonal role remains still elusive, 
AT2 subtype receptor seems to be regulated by intracellular cations, particularly Na
+ 
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(Tamura et al., 1999). AT2 activation may antagonize, under physiological conditions, 
AT1-mediated effects (Ciuffo et al., 1998; Yamada et al., 1998) by inhibiting cell growth, 
and by promoting apoptosis and vasodilation (Hayashida et al., 1996; Horiuchi, 1997a,b; 
Gallinat et al., 2000; Unger, 1999; Siragy, 2000).  In contrast to extensive data on the 
molecular and cellular functions and pathophysiological significance of AT1 receptor, the 
role of AT2 receptor in cardiovascular diseases remains to be defined.  
 
1.1.3   Actions of Ang II on Cultured Cardiac Myocytes 
 
Ang II exerts effects directly and indirectly on the cardiovascular system (Rogers and 
Lokuta, 1994). It directly stimulates cardiomyocyte excitation-contraction coupling, 
causing positive inotropic and chronotropic responses in cardiac muscle (Schomisch, 
1990; Ishihata, 1993), and indirectly influences these parameters by facilitating 
adrenergic neurotransmission (Blumberg, 1975).  In addition to these physiological 
actions, Ang II has been associated with pathological consequences such as myocardial 
ischemia, hypertrophy, and pressure overload (Morgan, 1991; Dostal, 1993). Although 
cardiac myocytes express both AT1 and AT2 receptors (Booz and Baker, 1996), almost 
all of the biological responses to Ang II reported so far are mediated by AT1 receptor. 
Accumulating evidence has established that Ang II causes hypertrophy of neonatal 
cardiac myocytes (Baker and Aceto, 1990; Baker et al., 1992; Sadoshima and Izumo, 
1993 & 1997) and adult myocytes (Wada et al., 1996; Liu et al., 1998; Ritchie et al., 
1998). In NRC, Ang II directly induced the fetal phenotype of gene expressions, such as 
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those of β-MHC, skeletal α-actin, and ANF, indicating the direct involvement of AT1 
receptors in cardiac gene reprogramming in vitro (Sadoshima and Izumo, 1993). 
Furthermore, Ang II stimulated the expression of immediate-early genes, including c-fos, 
c-jun, jun B, Egr-1, and c-myc (Sadoshima and Izumo, 1993). However, the significance 
of Ang II induced immediate-early genes expression in hypertrophy is unclear.  
 
Ang II, via AT1 receptor, activates a diversity of intracellular signaling cascades in NRC, 
although the role of such signaling cascades in myocyte hypertrophy or gene 
reprogramming remains to be elucidated.  Cardiac myocyte AT1 receptor couples to a 
heterotrimeric G protein, stimulates the activation of phospholiase C (PLC), and causes 
increases in inositol 1,4,5 trisphosphate (InsP3) and diacylglycerol (DAG). This in turn 
leads to an increase in the release of Ca2+ from intracellular stores and activation of 
protein kinase C (PKC).  In addition, it has been reported that Ang II activates a variety 
of kinases (Sadoshima et al., 1995; Kudoh et al., 1997; Takano et al., 1996; Sadoshima 
and Izumo, 1995), phospholipases A2 (PLA2) and D (PLD) resulting in increased 
generation of phosphatidic acid and arachidonic acid (Sadoshima and Izumo, 1997). Ang 
II also induces phosphorylation of various kinases, signal transducers (Kodama et al., 
1998).  However, it remains unclear whether Ang II can indeed simultaneously activate 
all of the above-mentioned signaling cascades in myocytes.  Furthermore, it remains to be 
determined to what extent each signaling cascade is involved in Ang II-induced cardiac 
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myocyte hypertrophy and gene reprogramming seen in pathological cardiac hypertrophy 
states encountered in vivo. 
 
 
 
1.1.4 Ang II Evoked Ca2+ Signaling in Cultured NRC 
The presence of all components of the RAS in neonatal rat cardiomyocytes (NRC) is 
consistent with its role in maintaining cardiovascular homeostasis (Booz and Baker, 
1996; Touyz et al., 1996a).  Ang II regulates cardiac contractility and growth via 
stimulation of AT1 receptors (Booz and Baker, 1996; Touyz et al., 1996a). The multiple 
cardiac actions of Ang II are mediated by changes in [Ca2+]i (Rogers  and Lokuta, 1994).   
Ang II activates inwardly directed Ca2+ currents (Allen et al., 1988), giving rise to 
increased Ca2+-induced Ca2+ release from cardiac sarcoplasmic reticular stores (Kem et 
al.,1991).  Stimulation of AT1 receptors leads to Ca
2+ mobilization through the activation 
of PLC, resulting in the generation of InsP3 and DAG (Kem et al., 1991; Sadoshima et 
al., 1993a; Touyz et al. , 1996a & 2000).  The mechanisms governing the regulation of 
Ang II evoked increases in cystosolic free calcium ([Ca2+]i) level are not fully 
understood.  Besides enhancing the [Ca2+]i level, Ang II elicits complex intracellular 
signaling events that include the production of superoxide anions, the activation of 
several kinases as well as the alteration of cyclic nucleotides and nitric oxide (NO) levels 
(Touyz et al., 2000).  In addition, ANG II activates phospholipase (PLA2) and 
phospholipase D (PLD), resulting in elevation of arachidonic acid (AA)-derived 
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metabolites (Dulin et al., 1998; Lokuta et al., 1994; Nasjletti et al., 1998; Parmentier et 
al., 2001; Rao et al., 1994; Zafari et al., 1999). 
 
1.1.5 Vascular Actions of Angiotensin II 
 
Ang II mediates its effects directly by acting on Ang II receptors located on vascular 
cells, indirectly via the release of other factors, and possibly via cross-talk with 
intracellular signaling pathways of other vasoactive substances and growth factors. 
Except the main function of vasoconstriction, vascular smooth muscle cells have 
important synthetic properties during development and vascular remodeling and are the 
major source of extracellular matrix components of the vascular media (Katoh and 
Periasamy, 1996).  During blood vessel development, immature smooth muscle cells are 
in a dynamic state of growth and differentiation characterized by proliferation and 
migration (Glukhova et al., 1991). While in the adult vessel, the smooth muscle cells are 
quiescent with a fibroblast-like appearance, and are filled with contractile fibers (Gordon 
et al., 1990).  Although mature smooth muscle cells remain quiescent until injury or 
insult occurs, they undergo physiological hypertrophy in response to increased load 
(Bucher et al., 1982; Katoh and Periasamy, 1996). Ang II plays a role in these 
developmental processes, acting via AT1 and AT2 receptors, which are differentially 
expressed in vascular smooth muscle cells (VSMC) during normal development and 
during pathological processes.  In cardiovascular disease states, smooth muscle cells 
undergo hyperplasia and/or hypertrophy as an adaptive or reactive response (Geisterfer et 
al., 1988; Berk et al., 1989; Paquet et al., 1990; Stouffer and Owens, 1992; Dubey, 1997; 
Touyz and Schiffrin, 1997a; Touyz et al., 1999b). This may be critical in vascular 
remodeling associated with hypertension, atherosclerosis, or neointimal formation.  Ang 
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II has been established to stimulate protein synthesis and induce cellular hypertrophy in 
cultured VSMC via activation of AT1 receptors (Geisterfer et al., 1988; Berk et al., 
1989).  This pathway is considered to contribute in a major way towards the development 
of various vascular diseases including hypertension and atherosclerosis (Gibbons and 
Dzau, 1994).  A growing body of evidence shows that AT1 receptor activation in cultured 
VSMC, coupled to the G protein Gq, causes not only activation of PLC-β leading to 
increases in DAG and [Ca2+]i but also activation of multiple signal transduction 
cascades. 
 
While Ang II evokes vasoconstriction, growth, migration, production of extracellular 
matrix components, and inflammation via AT1 receptors, it promotes apoptosis, and 
attenuates proliferation and hypertrophy via AT2 receptors activation (Allen et al., 2000; 
Siragy, 2000). In addition, the bioactive end products of the RAS, such as Ang-(1-7), 
may also modulate vascular responses to Ang II. As a naturally occurring competitive 
inhibitor of Ang II, Ang-(1-7) is a potent vasodepressor and has antihypertensive effects. 
It can increase the release of vasopressin, stimulate synthesis and release of vasodilator 
prostaglandins, potentiate the actions of bradykinin and release nitric oxide (Ferrario et 
al., 1997).  The receptor mediating the vascular actions of Ang-(1-7) has been described 
as a non-AT1/AT2 subtype (Ferrario et al., 1997). Although the precise role of this 
peptide in the physiological and pathophysiological regulation of vascular function 
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remains unclear, its potential to antagonize AT1-mediated actions suggests that Ang-(1-7) 
may be involved in the modulation of vascular tone by promoting vasodilation. 
 
1.1.6   Ang II evoked Ca2+ Signaling in Blood Vessels 
Ang II plays an important role in both the physiological maintenance of arterial pressure 
and the pathogenesis of hypertension by regulating the vasoconstriction and growth via 
multiple intracellular signaling pathways that employ [Ca2+]i as a second messenger 
(Touyz et al., 2000).  [Ca2+]i is a fundamental regulator of VSMC contraction and 
proliferation (Clapham et al., 1995).  Most of the vascular actions of Ang II are mediated 
predominantly by activation of the AT1 subtype (Touyz et al., 2000). Stimulation of AT1 
receptors leads to Ca2+ mobilization through the activation of PLC, resulting in the 
generation of InsP3 and DAG (Kem et al., 1991; Sadoshima and Izumo, 1993a; Touyz et 
al., 1996a & 2000).  Ang II-induced exaggerated [Ca2+]i response leads to 
vasoconstriction, vascular hypertrophy and hypertension in SHR (Touyz  et al., 1997b). 
The mechanisms underlining the regulation of Ang II evoked increases in [Ca2+]i level 
are not fully understood.   
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1.1.7 Ang II Evoked Increase in Intracellular Free Calcium 
Concentration 
Ang II-stimulated Ca2+ signaling is complex and occurs via multiple pathways to elicit 
an integrated Ca2+ signal. Ang II typically mediates a biphasic [Ca2+]i response 
comprising a rapid initial transient phase and a sustained plateau phase (Dostal, 1990; 
Touyz et al., 1994; Assender et al., 1997; Touyz and Schiffrin, 1997b). Both AT1A and 
AT1B receptors have been shown to mediate calcium signaling in rodent VSMC (Zhu et 
al., 1998b). The first [Ca2+]i transient is generated primarily by InSP3-induced 
mobilization of intracellular Ca2+ and to a lesser extent by Ca2+-induced Ca2+ release 
(Touyz and Schiffrin, 1997b). The second [Ca2+]i phase, which appears to contribute to 
the sustained Ang II-induced vasoconstriction, is dependent on external Ca2+ and is the 
result of transmembrane Ca2+ influx (Rembold, 1992; Ruan and Arendshorst, 1996a; 
Inscho et al., 1997; Iverson and Arendshorst, 1998; Touyz et al., 1999c). The exact 
mechanism that contributes to Ang II stimulated Ca2+ influx is unclear but it may involve 
voltage-dependent calcium channels, Ca2+-permeable, nonspecific dihydropyridine-
insensitive cation channels, receptor-gated Ca2+ channels, Ca2+-activated Ca2+ release 
channels, and activation of the Na+/Ca2+ exchanger (Arnaudeau et al., 1996; Lu et al., 
1996). In addition to InSP3-mediated mobilization of intracellular Ca
2+ and influx of 
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extracellular Ca2+, tyrosine kinase-dependent increases in [Ca2+]i have been 
demonstrated in VSMC (Hughes and Bolton, 1995; Touyz et al., 1996a; Di Salvo et al., 
1998). 
 
1.2   Leukotrienes 
1.2.1   Introduction 
 Leukotrienes (LTs) are a family of lipid mediators involved in acute and chronic 
inflammatory and allergic diseases (Samuelsson, et al., 1983). They are 5-lipoxygenase 
(5-LO) derived metabolites of AA.  LTs are normal products of continuous metabolism 
of AA and present in many cells and organs. While little is known about the effects of 
LTs on physiological functions, studies have shown that LTs play an important role in the 
mediation of several pathophysiological processes such as generalized or local immune 
reactions, inflammation, asthma, shock, and trauma.  LTs exert effects on many essential 
organs and systems, including the cardiovascular system, the pulmonary system, the 
central nervous system, the gastrointestinal tract, and the immune system. In these 
organs, the effects of LTs are mediated by specific LT receptors. Therefore, identification 
of LTs and characterization of their systemic and local pathological effects, together with 
characterization of their structure-activity relationships, are fundamental to developing 
LT antagonists or synthesis inhibitors that might prevent or reverse LT-dependent 
reactions (Feuerstein and Hallenbeck, 1987). 
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1.2. 2   Discovery of Leukotrienes 
It is well known that there are important interactions between the AA and its 
cyclooxygenase (COX) products, and the anaphylactic mediator, slow-reacting substance 
of anaphylaxis (SRS-A) and the nonimmunologically generated SRSs that promote 
bronchospasm. COX inhibitors such as aspirin or indomethacin attenuated the production 
of prostaglandins (PGs) from human or guinea pig lung during antigen challenge but 
greatly increased the generation of SRS-A.  The generation of SRS-A and SRS was 
increased by the addition of fatty acid substrates for lipoxygenase (LO), suggesting that 
the SRSs are the product of a LO (Piper, 1984).  Samuelsson et al first observed that AA 
is oxygenated at C-5 in a study of the transformation of polyunsaturated fatty acid in 
rabbit polymorphonuclear leukocytes (PMNL) in 1976. Subsequently a number of 
derivatives, including Leukotriene B4 (LTB4) were identified by the same group.  
Extension of these studies in 1979 led to the discovery of the pivotal epoxide 
intermediate, 5(S)-trans-7, 9-trans-11,14-cis-eicosatetrenoic acid (leukotriene A4, LTA4 ) 
and the elucidation of the structure of SRS-A as a group of cysteinyl LTs (CysLTs), 
namely LTC4, LTD4 and LTE4 (Feuerstein, 1984; Samuelsson, 2000). 
 
1.2.3   Biosynthesis of Leukotrienes 
Originally, biosynthesis of LTs has been observed in a variety of cells including PMNL 
(Hansson and Radmark, 1980), macrophages (Rouzer et al., 1980), mast cells (Razin et 
al., 1982) and eosinophils (Jorg et al., 1982).  In addition, LTs are also found in lungs 
(Morris et al., 1980), heart (Evers et al, 1985), and brain (Lindgren et al., 1984).  More 
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recently, several lines of evidence also support the generation of LTs in blood vessels 
(Sjostrom et al., 2001; Maclouf et al., 1989; Samuelsson, 1983; Piomelli et al., 1987). 
LT is generated from the AA in the present of  activated 5-LO. This enzyme uses AA as 
substrate and directs the formation of the highly unstable allylic epoxide LTA4, which 
then becomes a substrate, depending on the cellular environment and the availability of 
the enzymes, for either a specific LTA4 hydrolase enzyme or a LTC4 synthase enzyme. 
The LTA4 hydrolase expressed in neutrophils acts to add a water molecule to the epoxide 
leading to the generation of a chemically stable and steriospecific product known as 
LTB4. LTC4 synthase is expressed in various types of hematopoietic cells such as mast 
cells, basophils, eosinophils and monocytes/macrophages. Recent study has shown that 
LTC4 synthase is also present in human umbilical vein endothelial cells (Sjostrom et al., 
2001).  The function of LTC4 synthase is to add a glutathione moiety to LTA4 resulting 
in the creation of the "peptide" LTs.  The peptide LTs comprises the sequential products-
LTC4, LTD4 and LTE4. LTD4 and LTE4 are the result of a successive cleavage of amino 
acids (Figure 1).  These three peptide LTs, namely CysLTs (CysLT), individually and 
collectively account for the potent biological activities of the SRS-A are classically 
considered as inflammatory mediators.  Beside 5-LO enzyme, there are other LO 
enzymes, which when stimulated oxidize AA at the 12 and 15 positions resulting in the 
formation of 12 HETE and 15 HETE respectively (Letts et al., 1987). 
 
 
 18
 
 
COX
Eicosanoids
TXA2 , PGI2
AA20 HETE
12
- L
O
CYP 450
LEUKOTRIENES
 
 
 
 
 
 
 
 
 
 
LTA4 , LTB4 , LTC4 , LTD4 , LTE4
5-LO-
Inactive5-LO-
Active
FLAP
MK-591
BAY u9773
CysLT1-R CysLT2-R
12 HETE
MK 571
AA 861
LTE4 Metabolites
 
 
 
 
 
 
 
Figure 1.  Schematic representation of the biosynthetic pathways of 5-lipoxygenase 
derived arachidonic acid (AA) metabolites.  The site of action of 5-LO inhibitors and 
CysLT antagonists are shown.  Note: AA861 is a selective 5-LO inhibitor. MK591 is a 5-
LO activating protein inhibitor (FLAP inhibitor) that inhibits activation of 5-LO. MK571 
is a CysLT1 selective antagonist whereas Bay u9773 is a dual CysLT1/ CysLT2 receptor 
antagonist. 
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1.2.4  5-LO and 5-LO Activating Protein 
1.2.4.1   5-LO and its Inhibitors 
5-LO has been purified from different types of leukocytes, as monomeric enzymes with 
molecular weights estimated to be between 72,000 and 80,000. It was abundantly present 
in monocytes/macrophages, dendritic cells, mast cells and neutrophilic granulocyte. 
Importantly, 5-LO is also present in the vasculature. The increased expression of 5-LO in 
pulmonary artery endothelial cells has been observed in disease status such as pulmonary 
hypertension and challenge. (Spanbroek et al., 2003; Soberman et al., 1985; Zhang et al., 
2002). The 5-LO pathway was abundantly expressed in arterial walls of patients afflicted 
with various lesion stages of atherosclerosis of the aorta, coronary, and carotid arteries. In 
addition, the number of 5-LO activity markedly increased in cells in advanced lesions 
(Spanbroek et al., 2003). 5-LO has a central role in LT biosynthesis. It catalyzes the 
conversion of AA to 5(S)-hydroperoxy-6trans-8,11,14-cis-eicosatetraenoic acid, and 
further to LTA4. The activity of 5-LO is Ca
2+ dependent; moreover, adenosine 
triphosphate, lipid hydroperoxide, cytokines and other nucleotides enhance 5-LO activity 
in a Ca2+ dependent manner.  In the resting cell, 5-LO is present in the cytosol.  When 5-
LO is activated in the presence of Ca2+, 5-LO from the cytosol is translocated to the 
nuclear membrane to promote LT biosynthesis (Yamamoto et al., 1984; Radmark et al., 
2000). 
 
Several compounds have been shown to inhibit 5-LO, thus preventing LT biosynthesis. 
AA-861, a 5-LO inhibitor, reduced the synthesis of the SRS-S by lung fragments of 
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sensitized guinaea pigs.  While AA861 also inhibited other LOs like 12-LO, however the 
IC50 value for inhibiting 12-LO were higher by two orders of magnitude.  Thus, AA-861 
was a relatively selective inhibitor of 5-LO at concentration range (<25 µM).  Although 
compounds such as BW755C, nordihydroguaiaretic acid, 15-Hydroxy-5,8,11,13-
eicosatetreenoic acid, were effective inhibitors of 5-LO, they were non-specific and less 
potent in comparison to AA–861. Thus, among 5-LO inhibitors, AA861, appears to serve 
as an useful biochemical and pharmacological tool to selectively block 5-LO mediated 
generation of LT and CysLTs (Yoshimoto et al., 1982). The site of action of AA861 in 
AA-derived metabolites is shown earlier (Figure 1, see page 18). 
 
1.2.4.2    5-LO-Activating Protein (FLAP) and FLAP Inhibitors 
The 5-LO activating protein (FLAP) is a novel 18-Kda leukocyte membrane protein with 
three transmembrane-spanning regions and two hydrophilic loops, functions as a 
membrane anchor for 5-LO. Both 5-LO and FLAP are necessary for cellular LT 
synthesis. FLAP is essential for the activation of 5-LO.  It was suggested that LT 
biosynthesis can be a two step process consisting of FLAP-independent binding of 5-LO 
to the membrane of the nuclear envelope, followed by FLAP-dependent activation of the 
enzyme (Brideau et al., 1992; Radmark, 2000). Studies regarding the subcellular 
localization have demonstrated that most of the FLAP is associated with the nuclear 
membrane, and some with endoplasmic reticulum (Peters-Golden et al., 1993). 
 
Biosynthesis of LTs can be attenuated by employing FLAP inhibitors. MK886 is a potent 
and specific inhibitor of leukotriene biosynthesis in vivo and in intact cells.  While 
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MK886 has no direct effect on 5-LO activity in cell-free systems, it exhibited high 
affinity for binding to FLAP (Gillard et al., 1989; Rouzer et al., 1990).  Inclusion of 
MK886 led to blockade of 5-LO by preventing the translocation of 5-LO from the cytosol 
and the subsequent activation of 5-lipoxygenase (Rouzer et al., 1990). MK591 is a 
structural analogue of MK886, differing in the nature of the indolyl-5-substituent.  It also 
inhibited 5-LO translocation and LT biosynthesis by a specific interaction with FLAP. 
MK591 is currently undergoing clinical evaluation as a potential agent for the treatment 
of asthma and inflammatory bowel disease. MK591 may have advantages over MK886, 
including increased bioavailability and increased activity, as reflected by an 
approximately six fold increase in potency in the human whole blood assay (Brideau et 
al., 1992; Prasit et al., 1993). 
 
1.2.5   CysLT Receptors 
The CysLTs exert their biological actions by binding and activating at least two distinct 
but related 7-transmembrane domain, G-protein coupled receptors, namely CysLT1 
receptor (CysLT1-R) and CysLT2 receptor (CysLT2-R). Both receptors are linked to PLC 
activation and Ca2+ mobilization. These receptors have been cloned, characterized; they 
are found to be localized to human lung smooth muscle, peripheral leukocytes, human 
embryonic kidney, rat vascular sooth muscle cells and heart cells (Lynch et al., 1999; 
Sarau et al., 1999; Heise et al., 2000; Figueroa et al., 2001; Kamohara et al., 2001; Martin 
et al., 2001; Mazzetti et al, BJP, 2003).  The potency characteristics of LTD4, LTC4 and 
LTE4 and synthetic antagonists have been elucidated (Lynch et al., 1999; Heise et al., 
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2000). Affinity characteristics of various ligands at CysLT1 and CysLT2 are: CysLT1: 
LTD4 > montelukast > pranlukast > MK571 > LTC4=LTE4= Bay u9773 >>LTB4. 
CysLT2: LTC4 = LTD4 > LTE4 = Bay u9973 > MK571 > pranlukast > montelukast. 
 
1.2.5.1   Characterization of CysLT1 Receptor 
 The complementary DNA (cDNA) for the CysLT1 receptor has been recently cloned, 
and encodes a 337-amino acid, G-protein-coupled receptor (GPCR) putatively having a 
7-transmembrane spanning domain (Lynch et al., 1999; Sarau et al., 1999). The major 
intracellular signaling pathway for activation of the recombinant CysLT1 receptor is 
linked to calcium release.  Studies have shown the presence of CysLT1-R mRNA in 
human airway smooth muscle, alveolar macrophages, peripheral blood monocytes, 
eosinophils (Lynch et al., 1999; Figueroa et al., 2001), EC (Sjostrom et al., 2001), VSMC 
(Mazzetti et al., 2003) and human embryonic kidney cells (Sarau et al., 1999).  The rank 
order of affinities of the CysLTs for the CysLT1-R defined with transfected cells is: 
LTD4>>LTC4>LTE4>>LTB4 (Maekawa et al., 2002). Another group has ranked the 
affinities of various CysLTs interacting at CysLT1-R as follows: 
LTD4>>LTC4=LTE4>>LTB4. The affinity of LTE4 for the CysLT1-R was 
approximately 200 fold lower than that of LTD4 (Lynch et al., 1999). 
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Although there is circumstantial evidence supporting the hypothesis that CysLT plays an 
important role in asthma, definitive proof requires clinical evaluation of potent and 
selective LTD4 receptor antagonists in the management of bronchial asthma. L-660,711 
(MK 571) is an extremely potent and highly selective LTD4 (but not LTC4) receptor 
antagonist on guinea pig ileum and human airway smooth muscle. Receptor binding 
assays and a variety of quantitative pharmacological studies have shown that MK571 
directly interacts with the LTD4 receptor to produce its pharmacological effects.  MK 571 
has a unique profile of activity, which represents a substantial improvement over first 
generation LTD4 antagonists such as the nonspecific antagonists FPL-55712 and LY-
171883 as well as the more functionally specific antagonists, L-649,923 and L-648,051. 
MK 571 has comparable affinity characteristics to two recently described high affinity 
LTD4 receptor antagonists, SKF-104,353 and ICI-198,615. Moreover, it is 100 times 
more potent than most first generation compounds at inhibiting LTD4 binding and 
contractile effects in both guinea pig and human bronchial smooth muscles. The 
pharmacological profile (high affinity binding to CysLT1-R, oral bioavailability, and long 
duration of action) indicates that this compound has the potential to be clinically 
efficacious in disease where LTD4 receptors are activated (Jones et al., 1989). 
 
The current agents in this class of compounds that have clinical relevance in the 
management of bronchial asthma are montelukast, zafirlukast, pranlukast and probilukast.  
They are potent competitors for the binding of radiolabelled LTD4 to the CysLT1-R with 
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the following rank order of potency: pranlukast = zafirlukast > montelukast > probilukast 
(Sarau et al., 1999).  The localization of the CysLT1-R in smooth muscle and alveolar 
macrophages correlates well with the antibronchoconstrictive and anti-inflammatory 
nature of these new therapeutics entities (Lynch et al., 1999; Martin et al, 2001; Ferreira 
et al., 2001). 
 
1.2.5.2   Characterization of CysLT2 Receptor 
 The human CysLT2 receptor was localized to chromosome 13q14 by radiation hybrid 
and somatic cell hybrid analyses.  Like CysLT1receptor, CysLT2 receptor is a putative 
seven transmembrane spanning domain G protein-coupled receptor. CysLT2 receptors are 
expressed on alveolar macrophages, airway smooth muscle, cardiac purkenjie cells, 
adrenal medullary cells and peripheral blood leukocytes and brain cells (Heise et al., 
2000). CysLT2-R mRNA levels are detected at high levels in the human atrium and 
ventricle and at intermediate levels in the coronary artery (Kamohara et al., 2001).  
Further analysis by in situ hybridization revealed that CysLT2-R mRNA is expressed in 
myocytes, fibroblasts and VSMC (Kamohara et al., 2001).  At CysLT2-R subtype, the 
agonist potency rank order is: LTC4=LTD4>>LTE4>>LTB4 (Heise et al., 2000; 
Nothacker et al., 2000; Maekawa et al., 2002).  The expected affinity of LTD4 for 
CysLT2-R was approximately 50-fold lower than that of LTC4 in radioligand binding 
studies, while LTC4 and LTD4 induced Ca
2+ mobilization with equipotency (Heise et al., 
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2000; Kamohara et al., 2001). It has been suggested that LTC4 could promote the 
development of atherosclerosis as a chemoattractant and exacerbate the disease as a 
contractile factor of the coronary artery.  This is proposed to be mediated via activation of 
CysLT2-R on VSMC (Kamohara et al, 2001). 
Further analysis using CysLT2-R agonist/antagonists would lead to the elucidation of the 
pathophysiological roles of CysLTs in the cardiovascular system. Bay u9773, is reported 
to function as a dual CysLT1/CysLT2 antagonist (Heise et al., 2000).  However, when 
Bay u9773 was administered alone, it activated CysLT2-R more potently than LTE4, but 
less potently than LTC4 or LTD4. Therefore, Bay u9773 is suggested as a selective 
agonist for the CysLT2 and that it could be a partial agonist. Thus, Bay u9773 could be 
used as a selective tool for examining the physiological roles of the CysLT2 receptor in 
cardiac, neuronal, endocrine, and inflammatory circuits (Nothacker et al., 2000). 
However, the identification and relative distributions of vascular CysLT1-R and CysLT2-
R and their regulation in pathological states have not been characterized. 
 
1.2.6    Leukotrienes in Health and Disease 
Peptide LTs have potent biological actions on a variety of smooth muscle preparations, 
whereas LTB4 is a chemokinetic and chemotactic agent that has relatively few smooth 
muscle stimulating actions (Piper, 1984).  
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1.2.6.1    Leukotrienes and Pulmonary System 
    The lungs of both humans and experimental animals have been shown to produce SRS-
A and LTs subsequent to immune and non-immune stimuli. The LT receptors have been 
characterized in lung parenchyma, bronchial tree, and pulmonary vessels (Piper, 1984; 
Feuerstein and Hallenbeck, 1987). Among LTs, LTC4 and LTD4 are about equally active 
in contracting isolated bronchi and pulmonary parenchymal strips from humans and 
experimental animals.  Patients with asthma are especially sensitive to these actions of 
LTs.  Furthermore, LTs promote mucous production from bronchial epithelial cells and 
decrease ciliary activity, both of which contribute to further airway obstruction in 
asthmatic patients (Feuerstein and Hallenbeck 1987; Henderson et al, 2002). The 
potential role of LTs in mediating asthma is further supported by recent demonstration 
that a selective CysLT antagonist ameliorated the attacks in asthmatic patients (Centanni 
and Santus, 2002). 
 
1.2.6.2  Cys LT- Paradoxical Effects in Vascular Preparations 
 In addition to their bronchoconstrictor effects, CysLTs are also important modulators of 
vascular tone. The paradoxical effects of CysLTs in vascular preparations, namely 
contraction and relaxation, are now well documented in a number of vascular 
preparations from various species.  Indeed, depending on the vascular tone, either under 
basal or norepinephrine (NE)-precontracted state, LTs are capable of inducing both 
vasodilatation and vasoconstriction (Smedegard et al., 1982).  These effects vary among 
various species investigated (Feuerstein and Hallenbeck, 1987; Stanke-Labesque et al., 
2000; Walch et al., 2000).  Initially, it was viewed that vascular tissues acquire LTC4 and 
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LTD4 via intracellular transfer from leukocytes.  Several studies have now demonstrated 
that CysLTs are generated in both EC and VSM tissues (Kuhn et al., 1983; Piper et al., 
1983; Feuerstein, 1984; Piomelli et al., 1987).  The main layer in the vascular wall, which 
produces LTs, is the adventitia, which is more abundant with tissue macrophages and 
mast cells. However, the medial layer is also capable of releasing 5-LO derived AA 
metabolites (Feuerstein, 1984). 
 
1.2.6.3   Vasoconstrictor Responses to CysLTs- Role in Hypertension 
The vascular preparations that showed profound vasconstriction to CysLTs were 
pulmonary veins and arteries (Hand et al., 1981; Hand et al., 1983), coronary vessels 
(Piomelli et al.,1987), cerebral arteries (Tagari et al., 1983), uterine arteries (Vincent et 
al., 1983), renal and mesenteric arteries (Rosenthal and Pace-Asciak, 1983; Schumacher 
et al., 1989). LTD4 potentiates the responses to α-adrenergic agonists in rat aortic rings 
(Lawson et al., 1988).  The presence of high affinity binding sites for [3H]LTD4 (linked 
to constrictor responses) have also been demonstrated in human saphenous vein and 
internal mammary artery (Allen et al., 1994). In some animal species, after systemic 
administration of CysLTs, there is an initial arteriolar constriction and rise in BP, 
followed by transient hypotensive period. This biphasic BP response to LTC4 and LTD4 
is characteristic of guinea pig, monkey and sheep (Michelassi et al., 1982; Smedegard et 
al., 1982) but is uncommon in various strains of rats (Iacopino et al., 1983; Pfeffer et al., 
1983). However, SHR are extremely sensitive to the cardiovascular effects of LTD4. 
They exhibit a biphasic response. The initial pressor response was found to result from an 
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intense vasoconstriction in most peripheral vascular beds, which contributes to a rise in 
total peripheral resistance.  The ultimate mechanism involved in the constrictor response 
to  CysLTs in vascular tissues is not clearly established. The myotropic COX products, 
TXA2 and PGs, mediate the major part of the constrictor actions of LTC4 and LTD4 in 
guinea-pig lung.  In rabbit and rat lung, however, the CysLTs were much less potent in 
contracting parenchymal strips and there was little evidence of the release of COX 
products (Omini et al.,1981; Piper et al.,1981). LTD4 evoked mesenteric vasoconstriction 
is also independent of thromboxane A2 receptor activation (Schumacher et al., 1989).  It 
has been shown that LTD4 is a potent vasoconstrictor agonist in SHR strain; the 
mechanism of action seems to be mostly direct, but in part PG mediated (Zukowska-
Grojec et al., 1982). The second hypotensive phase is associated with a progressive fall in 
cardiac output (CO) secondary to coronary vasoconstriction, reduced myocardial 
contractility and hemoconcentration, which may be caused by enhanced vascular 
permeability (Bayorh et al., 1984; Piper 1984; Zukowska-Grojec et al., 1985; 
Schumacher et al., 1989).  LTD4 evoked a much higher vasoconstrictor response in the 
perfused mesenteric vascular bed preparation isolated from 14 week old male SHR 
compared to the responses determined in preparations isolated from age-matched 
normotensive WKY strain (Shastri et al., 2001).  While these observations are consistent 
with the presence of vascular CysLT receptors linked to vasoconstriction, their detailed 
characterization and likely alterations in SHR is presently unknown and the aim of the 
present thesis is to address this issue at the level of VSMC.  
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1.2.6.4    Vasodilator Effects of CysLTs 
CysLTs are known to cause VSM relaxation in a variety of preparations from different 
species via two pathways which have currently been suggested to mediate this response. 
One involves the metabolites of AA via the COX enzymatic pathway and the other 
implicates products of L-arginine enzymatic pathway.  Although both pathways may be 
present and active in the endothelium in different regional vascular beds, only one of 
these enzymatic pathways may be dominant and responsible for the relaxation observed 
(Walch et al., 2000).  To characterize the influences of LTD4 on regional vascular beds, 
the effects of LTD4 on vasomotor tone in canine renal and superior mesenteric arterial 
rings were determined.  In NE preconstricted rings, LTD4 produced a dose-dependent 
relaxation in endothelium-intact ring preparations. Because relaxation induced by LTD4 
did not appear to be related to the release of COX metabolites (Secrest et al,1985). Later, 
they demonstrated that endothelium-dependent LTD4-induced relaxation of canine 
superior mesenteric artery was linked to cyclic GMP production (Secrest et al., 1988). In 
pulmonary veins, the dominant pathway for CysLT relaxation was dependent on nitirc 
oxide (NO) generation (Ortiz et al., 1995). In addition to LTD4, LTC4 also showed 
endothelium-dependent relaxation in isolated thoracic aorta and pulmonary arteries of 
guinea pig.  The vasodilator responses to these agonists were antangonized by LT 
antagonist, ICI-198615 (Sakuma, Gross et al., 1987; Sakuma and Levi, 1988).  Together, 
these observations indicate the presence of CysLT receptors on the endothelium and that 
the responses may be mediated by NO generation (Walch et al., 2000).  In contrast, both 
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LTD4 and LTC4 induced vasodilatation in isolated human saphenous veins were shown 
to be dependent on both NO and COX metabolite (Gleason et al., 1983). On the other 
hand, another report has suggested that LTC4 induced relaxation is mediated by the 
release of metabolites of COX pathway in human saphenous veins (Allen et al., 1992), 
Thus CysLT may promote endothelium-dependent activation of these pathways and the 
extent of recruitment of each pathway may vary between different vascular beds and 
amongst various species.  However, the receptors that mediate these divergent effects 
have not been characterized.  In isolated human pulmonary artery and veins, CysLT2-R 
activation has been shown to promote NO release. On the other hand, in guinea pig 
pulmonary artery and thoracic aorta, CysLT1-R has been suggested to be responsible for 
the CysLT mediated relaxation (Walch et al., 2000)  
 
1.2.6.5   Effects of CysLTs on Microcirculation 
During systemic or local allergic reactions, LO products cause profound changes in 
capillary permeability, indicating the potential role of LO products in the modulation of 
microcirculation. They enhance the capillary permeability and promote plasma 
extravasation from the intravascular to exravascular compartment (Feuerstein, 1984; 
Feuerstein, 1986). Intradermal injection of LTs result in prolonged erythema, wheal 
formation and pain sensation, yet the wheal is characterized by pallor due to arteriolar 
constriction (Soter et al., 1983). Although the effect of LTs to enhance capillary 
permeability was observed in many species, including humans, some species seem to be 
less responsive (e.g., the rabbit) (Ueno et al., 1981).  LTC4, LTD4 and LTE4 are 
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extremely potent in increasing vascular permeability in rat and guinea pig. The 
microcirculatory effects of CysLTs may bear significance not only in inflammatory 
processes, but also in the promotion of edema, an important pathological factor in tissue 
injury.  In addition, acute reduction in intravascular volume, loss of plasma proteins and 
impaired intracapillary oncotic pressure might well serve as additional factors in 
promoting CysLT-induced hypotension and shock (Feuerstein, 1984; Feuerstein, 1986). 
 
1.2.6.6    Cardiac Effects of CysLTs 
With the use of a variety of techniques, the presence of CysLT1 and/or CysLT2 transcripts 
in cardiac tissue has been identified (Heise et al., 2000; Kamohara et al., 2001; Lynch et 
al., 1999; Ogasawara et al., 2002). CysLTs have been shown to exert potent effects on the 
heart, contributing to heart failure (Kamohara et al., 2001). Leukotriene A4 hydrolase 
plays a critical role in the generation of CysLT, and its expression is elevated in the heart 
of Ang II-induced hypertensive rats, suggesting that Ang II may promote cardiac CysLT 
production (Ishisaka et al., 1999). Moreover, low concentrations of CysLT, specifically 
LTD4 and LTC4, have been shown to promote a positive inotropic effect in the rat heart 
(Karmazyn and Moffat, 1990). CysLTs also regulate cardiac function by causing potent 
vasoconstriction of the coronary vascular bed both in vivo and in vitro.  Similar to other 
actions of LTs, the strength of vasoconstriction varies in different species.  Studies 
conducted in several in vitro preparations have clearly demonstrated that LTC4, LTD4 
and LTE4 are potent constrictors of the coronary arteries.  They evoke a significant 
reduction in the coronary blood flow (Burke et al., 1982; Letts and Piper, 1982; 
Ezeamuzie and Assem, 1983; Roth and Lefer, 1983; Piomelli et al., 1987).  A decrease in 
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contractility occurred with the reduction in flow, but there were no changes in heart rate 
(Feuerstein, 1984; Piper, 1984). Therefore, CysLTs are potent agents modulating 
coronary VSM tone; to the extent of causing profound inhibitory effect on myocardial 
function.  However, some studies have also shown that CysLTs may also exert direct 
negative inotropic effect on the heart, which in turn may contribute to profound reduction 
in coronary blood flow (Burke et al. 1982).  Isolated heart preparations from SHR show 
greater sensitivity to cardiodepressant action of LTD4.  Cardiac hypertrophy and 
coronary wall thickening have been reported in SHR strain which make them more prone 
to myocardial damage (Zukowska-Grojec et al., 1982). Because LTs are related in a 
variety of immunological and inflammatory reactions, their potent myocardial depressant 
effects may play a role in cardiac dysfunction associated with these reactions (Burke et 
al., 1982). 
1.2.7 Relation between CysLT and Vasoactive Agonists  
 The pressor responses to sympathetic stimulation and exogenous agonists such as Ang II 
and AVP were remarkly inhibited in pithed SHR subjected to pretreatment with LTD4 for 
10 min (Bayorh et al., 1984).  This was attributed to the effects of LTD4 at various sites 
and these can be summarized as follows: i) generation of COX derived vasodilatory 
mediators (PGE2 and PGI2) in different vascular beds, ii) profound coronary 
vasoconstriction resulting in diminished CO, iii) increased permeability of the 
microcirculation resulting in plasma extravasation and tissue edema that could create 
mechanical interference to VSM contration, iv) attenuation of release of NE from 
peripheral sympathetic nerves (Bayorh et al., 1984). In contrast, a later study 
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demonstrated potentiation of the contractile effects of epinephrine and NE by LTD4 in rat 
aortic rings and this potentiation was abolished by incubation with CysLT antagonist, FP-
55712, but not by the COX inhibitor, indomethacin. These data suggested a specific 
cooperative interation of LTD4 with α adrenergic agonist evoked responses possibly 
involving VSM CysLT-R activation by LTD4 (Lawson et al., 1988). 
Many studies have shown that LO derived metabolites could contribute to the vascular 
actions of Ang II (Stern et al., 1989). Recently, Stanke-Labesque et al first reported 
CysLT-dependent vasoconstrictor responses to Ang II in human internal mammary artery 
(Stanke-Labesque et al., 2000).  Later, they showed that, although Ang II-evoked 
responses were similar between aortic rings of SHR and WKY, AA861 (5-LO blocker) or 
MK571 (CysLT1 selective antagonist) abolished the responses to Ang II to an extent of 
65% and 48% respectively in the SHR but not in WKY rings (Stanke-Labesque et al., 
2001).  Upon endothelium denudation, the inhibitory effect of MK571 was lost.  Based 
on these data, they concluded that Ang II stimulates the release of a contractile factor 
from the endothelium (not ET-1) subsequent to CysLT generation and CysLT1 activation 
(Stanke-Labesque et al., 2001).  These studies were the first to support a direct link 
between Ang II – CysLT signaling and vasoconstriction in the blood vessels of SHR. Our 
laboratory has addressed this issue using a resistance type vascular bed preparation by 
examining this issue in perfused mesenteric vascular bed ex vivo after isolation from SHR 
and WKY strains (Shastri et al., 2001).  The vasoconstrictor responses to Ang II, ET-1 in 
the MVB of SHR were significantly higher than WKY while the responses to KCl 
depolarization remained unaffected in the preparations of either strain.  Addition of either 
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AA861 or MK571 abolished the exaggerated vasoconstrictor responses to Ang II but not 
to ET-1.  In the same preparation, CysLT evoked vasoconstrictor responses were higher 
in the SHR with the rank order of efficacy being LTD4> LTC4> LTE4.  MK571 
attenuated these responses.  These data are consistent with the presence of vascular 
CysLT1 receptor mediated exaggerated responses to Ang II in SHR.  However, the 
underlining mechanism for the exaggerated response in SHR remains unknown.  
 
Besides enhancing [Ca2+]i level, studies have shown that Ang II elicits complex 
intracellular signaling events that include several mediators such as superoxide anions, 
cyclic nucleotides and alteration in NO levels (Touyz, 2000; Richard et al., 1998).  In 
addition, stimulation of AT1 receptors by Ang II leads to activation of several kinases, 
phospholipase (PLA2) and phospholipase D (PLD), resulting in elevation of AA-derived 
metabolites such as CysLT (Freeman et al., 1998; Luchtefeld et al., 2003; Dulin et al., 
1998; Lokuta  et al.,1994; Nasjletti et al.,1998; Parmentier et al., 2001; Rao et al., 1994; 
Touyz 2000; Zafariet al.,1999).  In addition to their well-known bronchiolar smooth 
muscle spasmogenic effect, CysLTs have been shown to enhance [Ca2+]i levels and 
evoke vasoconstriction (Mazzetti et al., 2003; Bouchelouche et al., 2001; Kamohara et 
al., 2001; Ochsner et al.,1996; Ogasawara et al., 2002; Pedersen et al., 1997; Shastri et 
al., 2001; Stanke-Labesque et al., 2001).  However, the evidence at the level of VSMC 
for the presence of CysLT receptors as well as regulation of CysLT production, CysLT 
receptor expression by Ang II have not been characterized so far. By monitoring the 
changes in [Ca2+]i levels evoked by Ang II in both primary cultures of NRC and cultures 
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of ASMC, this study attempted to elucidate CysLT dependent responses to Ang II in 
these cells.  
 
1.3  Roles of Ang II and CysLT in hypertensin 
1.3.1  Roles of Ang II in SHR 
SHR is an appropriate animal model of human essential hypertension. The pathogenesis 
of hypertension is multifactorial, as evidenced by studies showing polygenic inheritance 
(Dzau et al., 1992). The cellular and molecular mechanisms that contribute to 
hypertension still remain unknown.  However, it is well accepted that increased 
peripheral resistance plays a critical role in blood pressure elevation.  In SHR, the 
increase in vascular resistance has been attributed to multiple interacting factors, 
including structural alterations in small vessels, decreased endothelium-dependent 
vasodilation, and enhanced vascular reactivity to vasoconstrictor stimuli. (Folkow et al., 
1982)  Among the many vasoactive agonists that have been suggested in vascular 
hyperresponsiveness in hypertension, Ang II plays one of the most important roles. 
Whereas responses to ET-1, AVP, and NE have been demonstrated to be decreased, 
unchanged, or rarely increased, vascular reactivity to Ang II has been reported to be 
increased in vessels from SHR (Schiffrin et al., 1994; Touyz et al., 1996a; Resink et al., 
1989).  Altered Ang II–stimulated vascular responsiveness occurs early in the 
development of hypertension, and studies have shown increased [Ca2+]i and contractile 
effects of Ang II in SHR as young as 6 weeks of age (Touyz et al., 1994; 
Chatziantoniouet al., 1990).  
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The signaling pathways responsible for enhanced Ang II–evoked excitation-contraction 
coupling in hypertension are not fully understood, and the signaling processes involved in 
the prehypertensive phase may differ from those in the established phase of hypertension. 
In cultured VSMC isolated from adult SHR, Ang II stimulated PLC–mediated signaling 
is increased, with enhancement of [Ca2+]i and [pH]i responses relative to normotensive 
controls(Touyz et al., 1994; Heagerty et al., 1986). These effects are partially attributed to 
increased Ca2+ influx and mobilization and to enhanced activity of the Na+-H+ 
exchanger (Rosskopf et al., 1993; Rembold, 1992),  [Ca2+]i elevation and alkalinization 
play very important roles in causing vasoconstriction (Touyz et al., 1994; Heagerty et al., 
1986; Rosskopf et al., 1993; Rembold et al., 1992). They mediate actin-myosin 
interaction, crossbridge cycling, and VSM contraction (Rosskopf et al., 1993; Rembold et 
al., 1992) In addition to activation of the classic PLC–mediated signaling pathways 
commonly associated with Ang II, it has been evident that Ang II stimulates other 
signaling pathways including those dependent on tyrosine kinase and mitogen-activated 
protein kinase (MAPK). (Sauro et al., 1996; Berk et al., 1997; Butcher et al., 1993; Touyz 
et al., 1997a).  
 
1.3.2 Role of Ang II Evoked AA-derived Metabolites in Hypertension 
 Besides PLC, the AT1 receptor is also coupled to phospholipase (PLA2) and 
phospholipase D (PLD) resulting in arachidonic acid (AA)-derived metabolites (Nasjletti 
et al., 1998; Touyz et al., 2000; Schlondorff et al., 1987; Rao et al, 1994).  Ang II-evoked 
hypertrophic responses in rat VSMC are linked to elevations in non-cyclooxygenase 
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derived AA metabolites (Dulin et al., 1998; Muthalif et al., 1998; Zafari et al., 1999). 
There is evidence that Ang II-evokes free AA formation in both EC and VSMC and this 
in turn leads to the generation: i) cyclooxygenases derived metabolites: prostacyclin 
(PGI2) and/or thromboxane A2 (TXA2) as well as other prostaglandins, ii) cytochrome 
P450 oxygenase derived metabolites that leads to generation of vasoconstrictor products: 
20- and 19-HETEs, iii) region specific 5-,12-,15- lipoxygenases leading to the formation 
of -,12-,15-HPETEs and HETEs.  While the vascular actions of PGI2, TXA2 as well as 
the role of 20-HETEs, have been well characterized, no studies have implicated a 
definitive role for 5-LO-derived leukotrienes, subsequent to the formation of 5-HETES, 
in Ang II-evoked responses in VSM tissues.  A schematic diagram outlines how Ang II 
mediated generation of AA metabolites promotes CysLT generation (Figure 1 page 18).   
 
Non-selective lipoxygenase (LO) inhibitors such as phenidone reduced blood pressure 
(BP) in SHR and proteinuria in stroke-prone SHR (Nozawa et al., 1989; Munsiff et al., 
1992).  Ang II induced vascular hypertrophy and vasoconstriction were reduced by non-
selective LO blockers (Natarajan et al., 1994; Stern et al., 1990; Takai et al., 1999).  
Enhanced pulmonary vascular reactivity to agonists and pulmonary hypertension in a rat 
model was attenuated by treatment with a 5-LO blocker (Voelkel et al., 1996).  Recent 
studies by a group in France and work from our laboratory have shown that Ang II 
evoked vasoconstrictor responses in SHR were reduced by AA861, a selective 5-LO 
blocker (Shastri et al., 2001; Stanke-Labesque et al., 2001).  Before describing these 
findings, a brief note on the pharmacology of CysLT actions will be presented. 
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1.4  Ang II action is CysLT dependent  
1.4.1  CysLTs contribute to Ang II action in cardiovascular response 
Understanding the pathophysiology of hypertension at the cellular and molecular level 
will help to reduce the burden of cardiovascular diseases. While the significant role of 
CysLT as key inflammatory mediators of bronchospasm has been well recognized, their 
contributions to the regulation of cardiovascular function has not been fully appreciated 
until recently (Shastri et al., 2001 & 2003; Liu et al., 2003; Stanke-Labesque et al., 2000 
& 2001; Nasjletti, 1998; Natarajan et al., 1994; Stern et al., 1990; Allen  et al., 1994).  
Recent work from our laboratory suggests that exaggerated Ang II evoked 
vasoconstrictor responses in the SHR are dependent on CysLT generation and activation 
of CysLT1 receptors linked to Ca
2+ mobilization. Among the well known Ca2+ 
mobilizing peptide agonists [Ang II, AVP and ET-1], Ang II plays a key role in the 
regulation of cardiovascular function.  Most of the vascular actions of Ang II are 
mediated predominantly by the activation of the AT1 subtype (Dzau, 1989; Oliver and 
Sciacca, 1984; Timmermans et al., 1993; de Gasparo et al., 1995).  Consistent with this 
view is the demonstration by our laboratory that Ang II evoked much higher increases of 
[Ca
2+
]i than AVP and ET-1 in VSMC and NRC in primary culture (Gopalakrishnan et al., 
1991; Xu et al., 1991 & 1993).  Most experimental studies focusing on the role of Ang II 
in hypertension utilize SHR as the primary model (Shastri et al., 2001; Stanke-Labesque 
et al., 2001; Timmermans et al., 1993; Touyz and Schiffrin, 2000).  Ang II elicits 
complex, highly regulated intracellular signal transduction events that lead to both short-
term (vasoconstriction and hemodynamic alterations) and long term biological effects 
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such as proliferation, hypertrophy, and migration as well as inflammation of VSMC.  
Touyz and Schiffrin have reviewed this subject (Touyz and Schiffrin, 2000).  Besides 
activation of PLC to enhance InsP3 and DAG production as primary second messengers, 
Ang II also activates a variety of kinases to regulate VSM growth, promotes apoptotic 
signaling in cardiac fibroblasts via expression of some proteins (Hao et al., 2000), and 
induces a hypoxic factor in VSMC (Richard et al., 2000).  Ang II actions are also 
mediated by nitric oxide (NO) (Fernandez-Alfonso and Gonzalez, 1999), superoxide 
anions (Wang et al., 1999), cyclic nucleotides (Palaparti   et al., 1999) and MAP kinases 
(Meloche et al., 2000).  The major intent of the present thesis work is to examine whether 
CysLT would mediate Ang II-evoked responses in both cardiomyocytes and VSMC and 
whether this overactive pathway could contribute to exaggerated vasoconstrictor 
responses in the SHR.  
 
1.4.2 CysLT contributes to Ang II evoked Ca2+ Signaling  
Stimulation of AT1 receptors by Ang II leads to activation of PLA2 and PLD resulting in 
elevation of arachidonic acid (AA)-derived metabolites such as CysLT (Freeman et al., 
1998; Luchtefeld et al., 2003; Dulin et al., 1998; Lokuta et al., 1994; Nasjletti et al., 1998; 
Parmentier et al., 2001; Rao et al., 1994; Zafari et al., 1999).  CysLTs such as LTD4, 
LTC4 and LTE4 exert their actions via activation of CysLT1 and/or CysLT2 receptors  
that are linked to PLC mediated Ca2+ mobilization (Heise et al., 2000; Lynch et al., 
1999). CysLTs have been shown to enhance [Ca2+]i levels and evoke vasoconstriction 
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(Mazzetti et al., 2003; Bouchelouche et al., 2001; Kamohara et al., 2001; Ochsner, 1996; 
Ogasawara et al., 2002; Pedersen et al., 1997; Shastri et al., 2001; Stanke-Labesque et al., 
2001).  In rat VSMC, the hypertrophic responses to Ang II is suggested to be at least 
partially linked to generation of non-COX derived AA metabolites (Dulin et al., 1998; 
Parmentier et al., 2001; Natarajan et al., 1994; Nozawa et al., 1990; Sasaki et al.,1997). 
Recent studies have demonstrated that Ang II-evoked vasoconstrictor responses in rat 
aortic rings and perfused rat mesenteric vascular bed were reduced in SHR strain by the 
inclusion of AA861, a selective inhibitor of 5-LO, or MK571, a selective CysLT1 
antagonist (Shastri et al., 2001; Stanke-Labesque et al., 2001). These data suggested that 
Ang II enhances the production of AA-derived 5-LO metabolites, CysLT, which may 
contribute to the exaggerated vasoconstrictor responses to Ang II in SHR (Shastri et al., 
2001; Stanke-Labesque et al., 2001). Both Ang II and CysLT evoke intracellular Ca2+ 
mobiliztion.  However, no study has so far demonstrated that Ang II evoked Ca2+ 
mobilization in rat cardiomyocytes is linked to CysLT mediated Ca2+ mobilization. In 
the present study, one of the goals was set to explore this posibility. The presence of 5-
LO, CysLT1 and CysLT2 have been detected in VSMC especially in the diseased arteries 
(Luchtefeld et al., 2003; Allen et al., Circulation, 1998; Back et al., 2000; Walch et al., 
2002; Mazzetti et al., 2003). However, whether Ang II evoked Ca2+ mobilization is 
linked to CysLT generation in ASMC remains unknown.  Using minimally passaged 
cultured ASMC isolated from both WKY and SHR rats, we have attempted to address 
this issue. 
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2.   PRESENT INVESTIGATION 
 
2.1  RATIONALE  FOR THE STUDY 
 
Three major pieces of evidence provide the basis for detailed studies on Ang II - CysLT 
interactions in both NRC and ASMC.  
1.  CysLTs (LTD4, LTC4 and LTE4) elicit vasoconstriction in both aorta and perfused 
mesenteric vascular bed.  MK571 abolished the exaggerated responses to CysLT in the 
MVB of SHR confirming the presence of overactive vascular CysLT1 mediated event 
(Shastri S et al, 2001).  Therefore, detailed biochemical characterization of 
CysLT1/CysLT2 receptors in VSMC is important.  Therefore, we initiated studies using 
minimally passaged cultured ASMC (between 2nd and the 3rd passages).  
2.  Interestingly, the exaggerated vasoconstrictor responses to Ang II but not ET-1 were 
reduced by either 5-LO blockade or CysLT1 antagonism in the MVB of SHR.  Whether 
CysLT2 receptors are present and whether they contribute to, or oppose Ang II evoked 
vasoconstriction, has not been yet addressed. 
3. Ang II evoked much larger increases in [Ca2+]i than AVP and ET-1 in the primary 
cultures of NRC and ASMC (Xu et al., 1991 & 1993; Liu  et al., 1999).  The hypertrophic 
response evoked by Ang II in NRC and ASMC are attributed to elevated [Ca2+]i evoked 
by Ang II (Sadoshima  et al., 1995 a & b).  Low concentrations of LTD4 and LTC4 have 
been shown to promote a positive inotropic effect in the rat heart (Karmazyn et al., 1990).  
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Despite this evidence, there are no studies to demonstrate whether Ang II evoked Ca2+ 
mobilization is linked to CysLT generation in NRC and ASMC. While increased cardiac 
LTA4 hydrolase activity has been detected in rats that were made hypertensive by Ang II 
infusion (Ishizaka  et al., 1999), whether NRC and ASMC express CysLT receptors and 
whether Ang II evoked [Ca2+]i responses would be mediated by CysLT has not been 
addressed.   Therefore, the major aim of the present work is to address these key issues at 
the levels of NRC and VSMC.    
Based on the above, the following working hypotheses have been formulated. 
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2.2   WORKING  HYPOTHESES 
 
1. CysLTs are generated in both ASMC and NRC.  Both CysLT1/CysLT2 receptors are 
present on ASMC and NRC.  Activation of these receptors result in increases in 
[Ca2+]i levels.  There is increased number of cell surface receptors and/or increased 
expression of CysLT receptors in the ASMC of adult SHR in established phase of 
hypertension compared to age and sex matched normotensive WKY.  
 
2.   AT1 receptor mediated increases in [Ca
2+]i response evoked by Ang II is linked to 
AA-derived, 5-LO-dependent, CysLT generation in both NRC and ASMC.   CysLT 
dependent [Ca2+]i response to Ang II is exaggerated in cultured ASMC derived from 
SHR.  Inclusion of either AA861 (5-LO inhibitor) or the 5-LO activating protein 
(FLAP) inhibitor, (MK591), or the CysLT1 selective antagonist, MK571, attenuates 
this indirect CysLT mediated exaggerated peak [Ca2+]i responses to Ang II in both 
NRC and ASMC. The blockade of peak [Ca2+]i responses to Ang II is more 
pronounced in the ASMC of SHR compared to the responses seen in ASMC isolated 
from normotensive WKY.  
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2.3    BRIEF EXPERIMENTAL STRATEGY/DESIGN  
Our laboratory is adequately equipped for monitoring the basal and agonist(s)-evoked 
changes in cytosolic free calcium, [Ca2+]i, levels  in the primary cultures of NRC and 
minimally passaged cultured ASMC (Liu et al, 1999).  Therefore, the major goal of the 
present study is to examine whether LTD4 and LTC4 evoke increases in [Ca2+]i in NRC 
and ASMC in addition to examining whether Ang II evoked peak [Ca2+]i responses 
would be attenuated by AA861, MK591, MK571 and Bay u9773.   This is the core data 
and premise for expanding the scope of this project and the rationale for a more detailed 
study at the level of expression of CysLT receptors and its regulation. The following 
experiments constitute the strategy for the work.  
1 Preparation of primary cultures of NRC and measurement of [Ca2+]i changes to 
agonists (AVP, Ang II and ET-1) in both multiple and single cells using fura-2 
fluoresence measurement. 
2  Isolation and culture of ASMC from SHR and WKY strains and measurement of 
[Ca2+]i signals to agonists (AVP, Ang II and ET-1) in both multiple and single 
cells.  
3 Measurement of basal and agonist(s)-evoked changes in CysLT production in the 
culture medium of NRC and ASMC of SHR and WKY strains and whether it is 
regulated by AA861 and MK591.  CysLT levels are monitored using an enzyme 
immuno assay kit.  
4 Levels of expression of CysLT1 and CysLT2 in NRC and ASMC will be examined. 
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5 In addition, the differences in the levels of CysLT1 and CysLT2 mRNA expression 
between ASMC of SHR and WKY strains will be evaluated.  cDNA probes for 
human CysLT1 and CysLT2 have been obtained as a gift from Dr. Garry O’Neill, 
Merck-Frosst Canada and the probes have been amplified.  CysLT1 and CysLT2 
mRNA levels will be determined using Northern blot analyses.   
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3. MATERIALS AND METHODS 
3.1    Animals  
The care and use of animals conformed to the regulation stipulated by the University of 
Saskatchewan Animal Care Committee, which is similar to the guidelines established by 
the US National Institute of Health for the maintenance and use of experimental animals 
in our laboratories (NIH Publication No. 85: 23, 1996). Sprague-Dawley rats (both male 
and female), Male SHR and WKY rats were obtained from Charles River (St. Constant, 
Quebec, Canada) or from Harlan (Indianapolis, Indiana, U.S.A.) at an age of about 10 to 
12 weeks. They were housed in our animal center assigned to the Department of 
Pharmacology with due care under standardized conditions with a light/dark cycle of 12 h 
and a constant temperature of 22 ± 1 °C. The rats were fed ad libitum with food pellets 
(Purina Rat Chow) and tap water. The Sprague-Dawley rats (12 to 16 weeks) were used 
for breeding the neonatal rats. The SHR and WKY rats were utilized for experiments 
when they reached the age between 14 and 16 weeks.  
 
3.2 Chemicals and Reagents 
3.2.1 Agonists 
Angiotensin II (Ang II), arginine vasopressin (AVP), and endothelin-1 (ET-1) were from 
Bachem (Torrance, CA). LTC4, LTD4 and LTE4 were obtained from Cayman Chemicals, 
Ann Arbor, MI, USA. 
 
 
 
 47
3.2.2 CysLT synthesis inhibitors and receptor antagonists: 
The 5-LO inhibitor, AA-861 (2-[12-hydroxydodeca-5,10-diynyl]-3,5,6-trimethyl-p-
benzoquinone) was obtained from Cayman Chemicals, Ann Arbor, MI, USA.  Propionic 
acid,3-[[[3-[2-(7-chloro-2-quinlinyl)ethinyl]phenyl][[3-(dimethylamino)-3-oxopropyl] 
thio] methyl] thio]-,(E)- sodium salt (MK571 or otherwise called L660711), the FLAP 
inhibitor,(3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]2,2-
dimethyl propanoic acid) (MK591)  and losartan (AT1 selective antagonist) were 
received as  gifts by the kind courtesy of Merck-Frosst, Pointe Claire, Dorval, Quebec, 
Canada. BAY u9773 was obtained from Biomol Reseaerch Laboratories (Plymouth 
Meeting, PA). PD123319, 2-aminoethoxydiphenyl borate (2-APB) were purchased from 
Sigma Chemical Co (Oakville, ON., Canada).  
 
3.2.3 Reagents for cell culture 
Bromodeoxyuridine, collagenase (Type II), elastase (Type IV), soybean trypsin inhibitor, 
were purchased from Sigma Chemical Co (Oakville, ON., Canada). Trypsin, culture 
media, DMEM, new born calf serum, horse serum, penicillin-streptomycin-fungizone and 
glutamine were from GIBCO-BRL (Life-Technologies, Grand Island, New York, 
U.S.A.).  
 
3.2.4 Kits and reagents for northern blotting analysis 
RNA STAT-60TM for total RNA extaction was the product of Tel-Test, Inc. 
(Friendswood, TX). Northern MaxTM kit, BrightstarTM-Plus positive charged nylon 
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membranes, DECAprime TM II kit, and NucAwayTM Spin Column were products of 
Ambion. [∝-32P] dCTP (3,000 Ci/mmol, 10 µCi/µl) was purchased from Amersham 
Pharmacia Biotech , Inc. (Baie d’Urfe, Quebec, Canada).  QIAprep Spin Miniprep kit and 
QIAEX II Gel Extraction kit were purchased from QIAGEN, Inc. (Mississauga, Ontario, 
Canada). 
 
3.2.5 Other chemicals and kits 
Fura-2 AM and pluronic acid F-127 were from Molecular Probes (Eugene, OR). 
Analytical grade salts for the preparation of Krebs buffer were purchased from Sigma 
Chemical Co (Oakville, ON., Canada), BDH (Dartmouth, NS, Canada), Calbiochem (La 
Jolla, CA), BRL (Burlington, ON) or ICN Biomedicals Inc. (Costa Mesa, CA). The EIA 
kit for the measurement of total CysLT levels were obtained from Cayman Chemicals, 
Ann Arbor, MI, USA. 
 
3.3    Methods 
3.3.1  Cardiomyocyte culture   
The details of isolation and primary culture of ventricular myocytes from newborn (3 days 
old) Sprague-Dawley rats have been described earlier (Liu et al., 1999; Xu YJ et al., 1991 
& 1993).  In the present study, we improved the isolation procedures to prepare either 
purified cardiomyocytes or cardiac mesenchymal cells by introducing the modifications 
adopted by others (Lau et al, 1980; Simpson and Savion, 1982). Thirty to fourty newborn 
1-3 day old Spragur-Dawley rats were anesthetized and cardiac ventricles were removed 
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and placed in a petri dish containing 10 ml heparinized phosphate-buffered saline under 
aseptic conditions followed by washing with the buffer for 3 times. The tissues were cut to 
1 mm3 pieces and transferred to 25 ml of 0.10% trypsin solution. The tissues were 
digested for 10 min at 37°C with stirring, the first digestion solution was discarded and the 
subsequent supernatants were collected at 10 min time intervals. After centrifugation at 
600 x g for 3 min., the cell pellet was resuspended in DMEM and incubated in two to 
three 75 cm2 flasks for 3 hours at 37°C. While the mesenchymal cells attached to the 
flasks first, myocytes did not adhere during this short duration of incubation.  The attached 
mesenchymal cells were cultured in DMEM with 10% fetal calf serum. These cells were 
utilized in a few selected experiments to characterize [Ca2+]i response to agonists such as 
Ang II, AVP and ET-1. The unattached cardiomyocyte cell suspension was layered on 
either 6 well culture plates for CysLT assay or on flaskes or glass coverslips for 
fluorescence measurement.  Therefore, cells grown by this by this method contained 75-
80% cardiomyocyte by day 5 in primary culture. When bromodeoxyuridine (0.1 mM) was 
included, it selectivively inhibited the proliferation of a few mesenchymal cells and thus 
led to the presence of purified myocyte-rich (95% purity) preparations relatively devoid of 
fibroblasts or mesenchymal cells (Liu et al, 1999).  
 
3.3.2    ASMC isolation and culture   
The details of isolation and culture of ASMC from WKY and SHR rats have been 
described (Gopalakrishnan et al., 1991).  Rats were exposed to anhydrous diethyl ether 
until the induction of anesthesia and were immediately killed. All subsequent procedures 
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were done under sterile conditions inside the flowhood. Aortic vessels were carefully 
dissected out and cleared of fat.  After the intimal layer was gently scraped, the vessels 
were cut longitudinally and incubated for 10 min at 37oC in Hanks’ balanced salt 
solution (HBSS) containing 0.2% type II collagenase, 0.025% type IV elastase, and 
0.02% soybean trypsin inhibitor (all from Sigma Chemical). This ensured removal of the 
endothelial cells and the vessels were cleaned further to remove the remaining adventitia 
and fat using the teflon scraper.  The cleaned vessels were cut into small pieces (1-2 mm 
in length), digested in the fresh HBSS enzyme solution for 45 to 60 min at 37oC. The 
suspension was centrifuged at 200 x g for 5 min, and the pellet was resuspended in 10 ml 
of Dulbecco’s modified Eagle’s medium (DMEM) with 10% (vol/vol) new born calf 
serum and 10% (vol/vol) horse serum, L-glutamine (2mM), penicillin (100U/ml), 
streptomycin (100 µg/ml), and Fungizone (1µg/ml).  The dispersed cells were plated into 
a tissue culture flask and incubated at 37oC in a humidified 5% CO2 / 95% O2 
atmosphere.  After the cells adhered sufficiently to the bottom of the flask (3-4 days), the 
remaining cell and tissue debris were removed and replaced with fresh culture medium.  
 
3.3.3    ASMC passage and maintenance 
Confluent monolayers formed between 6 and 8 days after isolation. This was referred to 
as the primary culture. When the cells reached the stage of confluence, the culture 
medium was removed and the cells were treated with 0.06% trypsin for 2-3 min at 37oC 
until the cells started to show signs of detaching. This stage was identified 
morphologically under the microscope as and when the spindle shaped attached cells 
became rounded.  Trypsin was then quickly removed and the cells washed once with 
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DMEM.  Fresh culture medium was added to the flask and the cells were detached by 
scraping with a teflon scraper and resuspended by trituration using a transfer pipette.  The 
cells were then replated (in culture medium) at a split ratio of between 1:3 and 1:6  in 
either 6 well plates or 75 cm2 culture flasks. The culture medium was changed every 2-3 
days (throughout the period of maintenance of ASMC) and the cells multiplied to reach 
confluency in 3-5 days for each passage level. Sub-cultured cells were used between the 
2nd and 3rd passage levels. We have previously ascertained that [Ca2+]i responses to 
agonists were not significantly different between cells in primary culture and those 
maintained up to the fifth passage.  Smooth muscle morphology was routinely assessed 
by examination under microscope, and the level of contamination by fibroblasts was <3% 
of the total population of cells. Moreover, occasional verification studies confirmed that 
>90% of cells showed positive immunoflourescent staining with α-actin antibody, 
confirming smooth muscle characteristics of adherent cells.  
 
3.3.4    Cell viability examination 
Cell viability was routinely checked prior to experiments by trpan blue exclusion criteria. 
Dead or dying cells took up the blue dye while viable cells remained intact. Cell number 
was counted using a hemocytometer, Fisher counter and a microscope.  
 
3.3.5   Determination of [Ca2+]i using Fura-2 in dispersed NRC or ASMC 
The NRC or ASMC which were grown on flasks and reached confluence were maintained 
in serum-free DMEM for 24 hr.  The culture medium was removed and the cells were 
treated with trypsin at 37°C for 3 min. The cells were transferred to Krebs HEPES buffer 
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(composition in mM: NaCl 145, KCl 5, CaCl2.2H2O 1.8, MgCl2.6H2O 1.2, glucose 10, 
HEPES 10, and 0.2% bovine serum albumin [BSA] - pH 7.4), centrifuged (600 x g  for 3 
min at 4°C), and resuspended in the same buffer at a cell density of ~1.06 cells/ml. Fura-2 
acetoxy methyl ester (Fura-2 AM, Molecular Probes) prepared in dimethyl sufoxide 
(DMSO) at a working stock concentration of 5 mM was added. To facilitate the solubility 
of Fura-2 AM and ensure effective loading, a small concentration of the surface agent, 
pluronic F 127 (0.02%), was added to the fura-2AM solution. The final concentration of 
Fura-2 AM was 5 µM in the incubation at 37°C for 30 min. The cells were washed twice, 
centrifuged, and resuspended in the same buffer at a cell density of ≈ 1.06 cells/ml. The 
excitation signals (340/380nm) were determined using a fluorimeter designed to monitor 
fura-2 fluorescence (JASCO CAF-100 Ca2+ Analyzer, Japan Spectroscopic, Tokyo, 
Japan).  Details of calibration and determination of basal and agonist(s)-evoked increases 
in [Ca2+]i levels have been described earlier (Liu et al, 1999; Xu et al, 1991) as well as 
listed as below.   
 
3.3.6 Determination of [Ca2+]i using fura-2 fluoresence in adherent NRC  
After NRC grown on glass coverslips attained confluence (3 days), the cells were 
maintained in serum free medium for 24 hr.  The cells were washed twice in Krebs-
HEPES buffer (composition in mM: NaCl 145, KCl 5, CaCl2.2H2O 1.8, MgCl2.6H2O 
1.2, glucose 10, HEPES 10, and 0.2% bovine serum albumin [BSA] - pH 7.4).  Cells were 
loaded in the dark with fura-2 acetoxymethyl ester (final 5 µM) for 30 min followed by 
three buffer washes.  Coverslips were inserted into a microcuvette containing 500 µl 
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buffer at 37oC.  The excitation signals (340/380nm) were determined using the  
fluorimeter described above. Details of calibration and determination of basal and 
agonist(s)-evoked increases in [Ca2+]i levels have been described earlier (Liu et al, 1999; 
Xu et al, 1991) as well as listed as below.   
 
3.3.7    Fura-2 Fluorescence Measurement 
Experiments with dispersed cells were performed with a fluorimeter specially designed to 
monitor fluorescence (JASCO CAF-100 Ca2+ Analyzer, Japan Spectroscopic, Tokyo, 
Japan). The detailed methodology regarding the use of this equipment has been described 
earlier (Gopalakrishnan et al., 1991; Xu et al, 1991; Batra et al., 1993). For each 
determination, 400 µl of Fura-2 loaded NRC or ASMC cell suspension (containing 0.2 –
0.3 X 106 cells) was added to a cuvette maintained at 25°C with a stirring rate at 800 rpm. 
Our previous study have confirmed that no significant differences in Fura-2 fluorescence 
were noticed at either 25°C or 37°C, and dye leakage and photobleaching were minimal at 
25°C. Therefore, we carried out all the experiments at 25 °C.  The cells were subjected to 
excitation at 340 nm and 380 nm, and the emitted light collected at the photomultiplier 
through a 500 filter.  Free fura-2 maximally excites at 380 nm, whereas the Ca2+ bound 
form is maximally excited at 340 nm.  Thus, the 340/380 fluorescence ratio is a measure 
of fura-2 chelation to Ca2+ which is directly proportional to the rise in the levels of free 
Ca2+.  The ratio of fluorescence due to excitation at 340 nm to that at 380 nm (R340/380) 
was calculated by the analyzer.  Since intracellular free fura-2 is essentially trapped in the 
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cytosolic compartment and available to chelate Ca2+ only in this compartment, free Ca2+ 
can therefore be considered cytosolic free Ca2+, or [Ca2+]i. The basal level and the peak 
increase in the ratio of fluorescence were noted from the display monitor for the 
calculation of basal and maximal increases in [Ca2+]i.  The [Ca
2+]i levels at  basal and at 
the maximal increase evoked by agonists were calculated according to the formula [Ca2+]i 
= KD x (R-Rmin)/ (Rmax – R) x Sf2/Sb2 (Grynkiewicz et al., 1985). Rmax was obtained 
after the addition of 25 µl Triton-X-100 (10%), and Rmin was determined by adding 25µl 
of 100 mM EGTA (ajusted to pH8.5 with Tris Base).  KD (224 nM) is the affinity for fura-
2 binding to Ca2+, R represents the measured cellular ratio of fluorescence (340/380) or 
relative fluorescence detected in mode II.  Rmax, Rmin are ratios obtained in Ca
2+ 
saturating conditions in the presence of Triton X-100, and Ca2+ free conditions in the 
presence of EGTA respectively.   Sf2 and Sb2 values are the 380 nm excitation signals in 
the absence and presence respectively of saturating concentrations of Ca2+ determined in 
mode III. 
 
3.3.8   Single Cell Fura-2 Imaging   
NRC or ASMC grown on glass coverslips (Delta T Dish 0.15nm, Bioptechs Inc., Butler, 
PA) were maintained in DMEM for 3 days and changed to serum free medium for 24 hr.  
The cells were washed in Krebs-HEPES buffer and subjected to fura-2 loading and 
washing.  The dish was mounted on the stage of an inverted Olympus I X 70 
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epifluorescence microscope fitted with a UA po 20 x .5 objective.  The fura-2 
fluorescence images were acquired using a fast monochromatic integral 125W Xenon light 
source (SpectraMaster Monochromator, Life Science Resources, Perkin Elmer, 
Gaithersburg, MD) with a shutter speed for monitoring alternate 340 and 380 nm 
excitation signals every 200 msec.  Ratiometric signals at 340/380nm were acquired at a 
rate of 3 images per second.  The emission signal at 510nm was collected using a charge-
coupled device camera (Astrocam, Cambridge, England, UK).  The digitized signals were 
stored and processed using UltraVIEWTM Imaging System software (Wallac Imaging, 
Perkin Elmer Life Sciences, Gaithersburg, MD).  Ang II (50 nM) was added to the 
coverslips after acquiring images for the first 30 seconds to determine basal fura-2 
fluorescence.  Interacting agents were added to fura-2 loaded cells for 3 min prior to 
imaging.  Rmax and Rmin values were determined using Ca
2+ ionophore, bromoA23187 
(50 µM), and then by quenching with 50 µl of Tris (50 mM), EGTA (100 mM) solution 
(pH 8.5) at the end of each experiment.  Once these values were entered, the software 
program employed provided the absolute [Ca2+]i values for each cell using the 
Grynckiewicz equation.  
 
3.3. 9 Determination of Concentration-Response (C-R) Curves   
The concentration-response (peak [Ca2+]i) curves to agonists (Ang II, AVP, ET-1, LTD4 
and LTC4) were determined by successive incubations under similar conditions. CR 
determinations for LTC4 and LTD4 were performed in the buffer medium devoid of BSA. 
The same aliquot of cell suspension loaded with the same concentration of Fura-2 was 
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employed, thus it is reasonable to compare the results of graded C-R curves. Basal 
fluorescence ratio prior to agonist inclusion followed by the changes in fluorescence ratio 
after the addition of agonist, was recorded for a period of 4 to 5 min. The maximal 
increase in flurescence ratio (peak ratio) evoked by the agonist was noted, and these ratios 
were converted to levels according to Grynkiewicz et al., (1985). The CR determinations 
to agonists were also performed in the presence of optimal concentration(s) of 5-LO 
inhibitor, AA861 (either 10 or 30 µM) (Shastri et al., 2001; Stanke-Labesque et al., 2001; 
Walker et al., 2002), CysLT1 antagonist, MK571 (100 nM) (Lynch et al., 1999; Ruck et 
al., 2001; Shastri et al., 2001; Stanke-Labesque et al., 2001), dual CysLT1/CysLT2 
antagonist, BAY u9773 (100 nM) (Heise et al., 2000), AT1 selective antagonist, losartan 
(1 µM;) (Booz et al., 1996; Kem et al., 1991; Sadoshima et al., 1993a & 1995b), AT2 
selective antagonist, PD123319 (1 µM) (Booz et al., 1996; Kem et al., 1991;Goldenberg et 
al., 2001; Sadoshima et al., 1993a & 1995b; Touyz et al., 1996b), and the cell permeating 
inositoltrisphosphate (InsP3) blocker, 2-aminoethoxydiphenyl borate (2-APB, 50 µM) 
(Missiaen et al., 2001).  The concentrations of all these agents were carefully chosen to 
ensure their selectivity of inhibition/blockade as validated by previous reports.  Each agent 
was maintained in the cuvette for 3 min prior to agonist challenge.  In select experiments, 
the fura-2 loaded cells were washed and placed in Ca2+ free buffer with 1 mM EGTA (pH 
7.4) in the cuvette for 15 min prior to agonist challenge and fluorescence measurement.  
All the inhibitors or antagonists were added to the cell suspension 3 min. prior to the 
addition of the agonists and the corresponding fluorescence ratios were monitored.  
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3.3.10 Total CysLT measurement 
 NRC or ASMC grown on 6-well culture plates for 3 days (~ 0.3 - 0.5 x 106 cells/well) 
were maintained for the last 24 hr in 2 ml medium devoid of serum.  The medium was 
replaced with Krebs-HEPES buffer for the last 2 hr prior to stimulation with Ang II (100 
nM) for varying time intervals (from 5 to 360 seconds).  CR determinations for Ang II 
(100 pM -1 µM), AVP (100 pM – 1 µM) and ET-1 (100 pM – 1 µM) evoked increases in 
CysLT levels were determined 1 min after the addition of respective agonist(s) and all 
these assays were performed in duplicate. The responses to Ang II were also determined in 
the presence of AA861 (10 µM), MK591 (100 nM), losartan (1 µM) or PD123319 (1 µM).  
A 450 µl aliquot of culture medium was stored in siliconized tubes at –80oC.  Total CysLT 
levels were determined within ten days of storage by enzyme immunoassay (EIA) 
following the protocol provided by Cayman Chemicals (Ann Arbor, MI).  Total CysLT 
levels were assayed spectrophotometrically (405 nm for measurement of 
acetylcholinesterase activity) as outlined in the kit using Anthos HT1 96 well microplate 
reader (Anthos Labtec Instruments, Salzburg, Austria).  The lowest detection limit was 4.0 
pg/ml and the 50% (B/B0) ratio was 40 pg/ml.  The intra and inter assay coefficients of 
variation were 7.3 ± 2.5% and 5.8 ± 2.9% respectively.  Cells were counted and the data 
normalized to express the values as CysLT/ml /million cells. 
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3.3.11 Northern Blot CysLT1 / CysLT2 mRNA Measurement 
3.3.11.1 Total RNA extraction 
 
Total RNAs of NRC and ASMC were extracted as previously described (Chomzynski & 
Sacchi, 1987) by using RNA STAT 60TM reagent.  The instructions for the extaction 
were provided in the manual.  Serum-free DMEM was removed from the culture flasks 
and cells were lysed directly in flasks by adding the RNA STAT-60TM (3 ml/75 cm2 
flask) and passing the cell lysate several times through a pipette. The washing of cells 
before addition of the RNA STAT-60TM should be avoided as this increases the 
possibility of mRNA degradation. The cell lysate was transferred to a sterilized 14 ml 
centrifuge tube and stored for 5 min. at room temperature to permit the complete 
dissociation of nucleoprotein complexes followed by addition of 0.2 ml of chloroform per 
1 ml of the RNA STAT-60TM. The sample was covered tightly and shaken vigorously 
for 15 seconds and allowed to stay at room temperature for 2-3 min. The samples were 
centrifuged at 12,000 g (maximum) for 15 min at 4°C. Following centrifugation, the 
homogenate separates into two phases: a lower red phenol chloroform phase and the 
colorless upper aqueous phase. RNA remains exclusively in the aqueous phase whereas 
DNA and proteins are in the interphase and organic phase. The volume of the aqueous 
phase is about 60% of the volume of RNA STAT-60TM used for lysing the cells. The 
aqueous phase was trasnsferred to a fresh sterilized tube and mixed with isopropanol (0.5 
ml of isopropanol per 1 ml of the RNA STAT-60TM used). The samples were left at 
room temprature for 5-10 min and then centrifuged at 12,000g for 10 min. at 4°C. RNA 
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precipitate (often visible before centrifugation) forms a white pellet at the bottom of the 
tube. The supernatant was removed and the RNA pellet was washed once with 75% 
ethanol and the supernatant was discarded and the pellet was resuspended, vortexed and 
subjected to subsequent centrigugation at 75,00 x g for 5 min at 4 °C. Then, 1 ml of 75% 
ethanol per 1 ml of RNA STAT-60TM was added and it was subjected to 
homogenization. At the end of procedure, the RNA pellet was briefly subjected to air-
drying and dissolved in diethylpyrocarbonate (DEPC) treated Rnase-free water. 
 
3.3.11.2   Quantitation of Isolated total RNA 
The amount and purity of total RNA was determined by spectrophotometer. The 
concentration of RNA in solution was calculated based on an optical density of 1.0 being 
equal to 40 µg/ml RNA. The purity was assessed as the ratio of fluorescence at 260 nm to 
that at 280 nm. 
 
3.3.11.3   RNA electrophoresis 
 
Isolated total RNA was electrophoresed using the protocol described ealier (Pelle and 
Murphy, 1993).  RNA samples (50 µg/well) and molecular weight standards were first 
mixed with 3 times the volume of formaldehyde loading buffer provided with the 
NorthernMaxTM kit. To denature the RNA secondary structure, the mixture was 
incubated at 65°C for 15 min followed by rapid transfer to ice. The sample was then 
loaded onto 1.0% agarose gel dissolved in denaturing gel buffer with 0.1 µg/ml ethidium 
bromide. MOPS gel running buffer was employed for the electrophoresis. The 
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electrophoresis was carried out at a charge of 5V/cm of gel allowing the RNA to traverse 
the gel. The gel was then visualized under uv light and photographed. 
 
3.3.11.4   Transfer of RNA to nylon membrane 
The RNA was transferred from the agarose gel to an Ambion’s BrightStar-PlusTM 
membrane by using a downward transfer assembly modified from the method develpoed 
by Chomczynski (1992) and following the procedures provided with the kit. After 
transfer, the RNA on the membrane was crosslinked using a U.V. Stratalinker (1,200 
joules). 
 
3.3.11.5    Preparation of probes 
 
3.3.11.5.1   Bacterial trasformation 
 
100 ng of plasmid DNA containing either human CysLT1 or CysLT2 cDNA fragments 
was added to 200 µl of DH5α competent cells mixed and stored on ice for 30 min. The 
mixture was then incubated at 42°C for 90 seconds and then quickly chilled on ice for 1-2 
min. 1 ml of LB medium (1% bacto-trpptone, 0.5% bactoyeast extract, 1% NaCl, pH 7.0) 
was added to each mixture.  The competent cells were then incubated at 37°C with 
shaking at a rate of 225 rpm for 1 h. Different volume of transformed bacterial cells were 
spread over the surface of agar LB medium on 1.5 % agar with 100µg/ml ampicillin. The 
plates were incubated overnight at 37°C in an inverse position. 
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3.3.11.5.2    Isolation of plasmid DNA 
The procedure for isolation of plasmid DNA was modified from an earlier methodology 
(Sambrook et al., 1989). Different colonies picked up from each plate were cultured 
overnight at 37°C with vigorous shaking in 10 ml LB medium with 100µg/ml ampicillin.  
5 ml of the culture was centrifuged at 12000g at 4°C for 10 min.  The plasma DNA was 
isolated by using a QIAprep Spin Miniprep kit and following the protocol provided with 
the kit. The isolated DNA was dissovled in 50µl elution buffer (10 mM Tris-.Cl, pH 8.5) 
and stored at -20°C.  
 
3.3.11.5.3    Recovery of CysLT1 or CysLT2 cDNA fragments from 
plasma DNA 
Both CysLT1 and CysLT2 cDNA were recovered from the corresponding plasmid DNA 
by a digestion at 37 °C for 1 h using restriction enzyme Pme I. The cDNA were separated 
by 1% agrose gel electrophresis. Bands of cDNA fragments of CysLT1 and CysLT2 
receptor were cut under U.V. light. The cDNA fragments were then isolated and purified 
from the gel by utilizing a QIAEX II Gel Extraction kit by following the procedures 
provided with the kit. The purified cDNA fragments were finally dissolved in 40 µl 
elution buffer (10 mM Tris.Cl, pH 8.5) and the concentrations were determined by 
spectrophotometer following the procedure described earlier. An optical density of 1.0 
corresponds to 50 µg/ml double stranded DNA. The cDNA was then stored at -20°C.  
 
3.3.11.5.4   Radiolabeling  of CysLT1 or CysLT2 cDNA 
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Labeled nucleotides were incorporated in DNA synthesized by an oligo-labeling method 
(Feinberg & Vogelstein, 1983). The DECAprimeTM II random priming DNA labeling 
kit  (Ambion) was used.  25 ng of cDNA was used for labeling.  The cDNA fragment 
solution was mixed with 2.5 µl of 10X decamer solution heated in at 95°C for 3 min and 
then chilled on ice. 10 µl of denatured DNA/Decamer Mix, 5.0 µl of 5X Reaction buffer 
containing unlabeled dNTP’s mixture, 5.0µl [∝-32P]dCTP (3,000 Ci/mmol, 10 µCi/µl), 
1.0 µl Exonuclease-free klenow fragment of DNA Polymerase I and 4.0µl of nuclease-
free H2O were then mixed and followed by  incubation  for 10 min at 37 °C. The reaction 
was terminated by adding 1 µl of 0.5 M EDTA.  The radiolabeled probe was then 
separated from the incorporated dCTP through a NucAwayTM Spin Column. 
 
3.3.11.6  Northern hybridization 
Northern blotting was performed using Northern MaxTM kit following the instructions 
provided with the kit. A sample of 60 µg total RNA was denatured and size-fractionated 
on a 1% formaldehyde-agarose gel, transferred onto the Brightstar-PlusTM positive 
charged nylon membranes and immobilized by UV crosslink. CysLT1, CysLT2 and β-
actin DNA probes were labeled with 32P using DECAprime TM II kit. A minimum of 10 
ml of ULTRAhyb solution per 100 cm2 of membrane was used and the membrane was 
prehybridized for 30 min at 42°C. The labeled probes were diluted 10 times with 10 mM 
EDTA and incubated at 90 °C for 10 min followed by addition of 1.0 ml of ULTRAhyb. 
The denatured probe was transferred to the hybridization solution. The blot was 
hybridized overnight (20 hr) at 42°C.  The membrane was washed twice for 5 min at 
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room temperature using the Low stringency Wash Solution which is equivalent to 2 X 
SSC, 0.1% SDS. Then the membrane was washed twice for 15 min at 42°C with High 
Stringency Wash Solution which is equivalent to 0.1 X SSC, 0.1% SDS. The membranes 
were exposed to X-film at –70 °C in the presence of an intensifying screen for 24 hrs 
followed by visualization and quantification using a Phosphor Imager (Molecular 
Dynamics). 
 
 3.4    Statistical analysis   
Experimental values are reported as means ± SEM of a minimum of five separate 
experiments performed on different days using different batches of NRC and ASMC.  
Comparison of mean values was performed by ANOVA (Super ANOVA software).  
Simultaneous multiple comparisons were assessed using Scheffe’s F-test and the 
concentration of agonist required to produce 50% of the maximal response (EC50) and the 
maximal increase in [Ca2+]i (Emax) values attained for each agonist were derived from log 
CR curves. 
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4.  RESULTS 
4.1 Results from Studies Using NRC 
4.1.1 Comparison of the characteristics of myocytes and non-myocytes (fibroblasts) 
The distinguishing characteristics of either purified myocytes or non-myocytes 
maintained in primary culture are shown (Table 1 and Figure 2).  Inclusion of 0.1 mM 
BrdU led to single or clusters of myocytes in culture that showed distinct beating 
characteristics with cells depictiting the morphological features of a round small nucleus 
with either one or at the most two nucleoli.  In addition, the cytoplasm stained red with 
myocytes under Mayer’s haemalum-eosin staining.  These features are consistent with the 
cells having characteristics of myocytes as shown in pictures (Figure 2a and c) under high 
and low powers respectively.   In contrast to myocyte morphology, the non-myocytes 
showed characteristics of oval larger nucleus with two or more nucleoli (as shown in 
Figure 2b).  In addition, the cytoplasm stained pale blue in the presence of Mayer’s 
haemalum-eosin staining.  Thus, in the absence of 0.1 mM BrdU in the medium, non-
myocyte cells proliferated such that the myocyte preparations yielded population of cells 
with 10-20% contamination of non-myocytes (Figure 2d).  Thus, purified myocytes were 
utilized in most of the experiments described in the present study.  Studies employing 
purified non-myocytes shown in Figure 2b were limited to comparison of the 
characteristics of [Ca2+]i signals to peptides agonists with those data obtained using 
purified myocytes. Thus, the elucidation of morphological characteristics and the 
comparison of [Ca2+]i signaling data assured that the responses obtained in the present 
study indeed arise due to responses to agonists from the myocyte-rich preparation. 
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Table 1 
      Distinguishing cardiomyocytes from non-myocyte     
           (fibroblast) under light microscope 
                                    MYOCYTE                   NON-MYOCYTE     
Beating                               Yes                                        No 
Cytopalsm                   thick, dark                         thin, phase-luscent 
Nucleus                        round, small                           oval, larger 
Nucleolus                        1 or 2 (10%)                         2 or more 
Mayer’s haem alum-eosin staining 
Beating                              no                                              no 
Cytopalsm                        red                                        pale blue 
Nucleus                      spherical, small                         oval, larger 
Nucleolus                        1  or  2                                        several 
(Lau et al., 1980; Simpson and Savion, 1982) 
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4.1.2 Comparison of [Ca2+]i data for adherent and dispersed purified myocytes 
The mean basal or resting [Ca2+]i values, as determined by the Fura-2 fluorescence 
(25°C) in the present study varied between 35 - 74 nM and 78 - 135 nM for adherent and 
dispersed myocyte preparations respectively.  Thus, the observed mean  ± SEM resting 
[Ca2+]i levels were significantly lower (p < 0.05) in adherent cardiomyocytes (56 ± 8 
nM) compared to data obtained using dispersed cell suspensions (99 ± 8 nM). Since Fura-
2 fluorescence data obtained using cell suspensions yielded consistent and reproducible 
data from different batches, it was utilized in the determination of concentration-peak  
[Ca2+]i response relationship for the present study.  On the other hand, except that 
adherent cells yielded quantitatively lower basal and peak [Ca2+]i responses to agonists, 
there were no qualitative differences between  responses obtained using adherent cells 
and dispersed myocyte suspensions. 
  
4.1.3 The Basal   [Ca2+]i levels in NRC  
The basal [Ca2+]i levels in normal Ca
2+ buffer was 99 ± 8 nM in multiple cells (n=54) 
and 121 ± 18 nM in single cells  (n=23) and the differences in resting levels observed by 
both methods were not significant (Table 2).  None of the interacting agents (AA861, 
MK571, MK591, BAY u9773, 2-APB, losartan or PD123319) affected the basal fura-2 
fluorescence. 
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Table 2.  Comparison of the basal [Ca2+]i levels measured in the normal ([Ca2+]e 1.8 
mM) or Ca2+ free bufer ([Ca2+]e 0 mM + 1.0 mM EGTA) by different methods 
determined using ASMC and NRC. 
 
                           Cell suspension Measurement        Single Cell Measurement
                                                  [Ca2+]e                                           [Ca2+]e
                                 1.8 mM       0 mM + 1.0 mM EGTA                           1.8 mM 
Cells 
ASMC
WKY                              97 ± 12                      70 ± 8                                                 112 ± 14       
SHR                               135 ±13 **                 95 ± 7 **                                            148 ± 16  
NRC
                                         99 ± 8                       70 ± 7                                                  121 ± 18  
 
 
*P<0.05, ** P<0.01 compared to respective groups in WKY.  * P<0.05, ** P<0.01 
compared to the respective groups in the absence of extracelular calcium. (0 mM + 1.0 mM 
EGTA).   
 
 
4.1.4   Effect of 5-LO inhibitor, AA861, and FLAP inhibitor, MK591 on Ang II 
evoked increase in [Ca2+]i levels in NRC 
 A representative tracing of Ang II evoked increases in fura-2 fluorescence ratio in the 
presence or absence of AA861 (10 µM) is shown (Fig 3 A & B).  Addition of Ang II led 
to a rapid concentration-dependent increase in the ratio of fura-2 fluorescence in multiple 
cells with maximal increases observed between 30 and 45 seconds; at 2 min after 
stimulation, the fluorescence ratio decreased to a steady state above the basal level.  The 
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CR curves to Ang II determined either in normal Ca2+ (1.8 mM) or Ca2+ free buffer is 
shown (Figure 4).  Addition of AA861 (10 µM), or MK591(100nM) led to a significant 
reduction in Ang II evoked increases in peak [Ca2+]i values (P < 0.01) in both normal 
and Ca2+ free buffer (Figure 4).  Moreover, the addition of AA861 did not affect either 
the time to attain the peak response or the time for reduction in peak [Ca2+]i to steady 
state level for varying concentrations of Ang II (Figure 3B). The effect of blockade on 
Ang II responses was similar when AA861 was increased to 30 µM.  Although the Emax 
values for Ang II were relatively lower in Ca2+ free medium, both AA861 and MK591 
evoked a similar degree of blockade (% reduction in Emax) of Ang II responses (right 
panel Figure 4).  These data demonstrate that both AA861 and MK591 decrease the Emax 
with no change in EC50 values for Ang II-evoked peak [Ca
2+]i responses (Table 3), 
suggesting that 5-LO derived leukotrienes contribute to Ang II evoked increases in peak 
[Ca2+]i levels via promoting the release of Ca
2+ from intracellular store. 
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Table 3.  Analyses of Ang II (10 pM – 10 µM), AVP (100 pM – 10 µM) and ET-1 (10 
pM – 100 nM) evoked increases in peak [Ca2+]i either in the presence or absence of the 
5-lipoxygenase (5-LO) inhibitor, AA861 (10 or 30 µM), or CysLT1 selective antagonist, 
MK571 (100 nM) in NRC maintained at 37oC.  
________________________________________________________________________ 
                                 Ca2+ 1.8 mM                         Ca2+ 0 mM + 1.0 mM EGTA   
Agonist               EC50 (nM)      Emax (nM)            EC50 (nM)        Emax (nM) 
ANG II  
Control                          12.6 ±  4.6           498 ± 30                13.5 ± 3.0          337 ± 20 
AA861  10 µM              13.9 ±  6.1           344 ± 15**            15.3 ± 4.1          230 ± 15** 
AA861  30 µM              15.1 ±  3.5           313 ±  28**           16.6 ± 4.5          195 ± 11** 
MK571 100 nM            16.8 ±  7.2            370 ±  22**           18.4 ± 6.1          236 ±  24** 
AVP  
Control                          18.9 ± 7.3        210 ± 11                     
AA861  30 µM              21.5 ± 6.6        199 ± 14 
MK571 100 nM             20.4 ± 7.8            212 ± 13 
ET-1 
Control                           6.3 ± 1.4         253 ± 18                     
AA861  30 µM              7.2 ±  2.1         232 ±  21 
MK571 100 nM             8.4 ±  2.3              228 ± 19 
 
 
Values shown are means ± SE of eight experiments.  The basal level [Ca2+]i was 90 ± 12 
nM in normal Ca2+ buffer.  AA861 or MK571 was maintained in the cuvette in the 
indicated buffer for a period of 3 min prior to the addition of the agonist.  The Emax to 
Ang II or AVP were attained at 1 µM whereas the Emax to ET-1 was reached at 100 nM.   
Note: Stimulation with either AVP or ET-1 was not performed in Ca2+ free buffer since 
no significant changes in EC50 and Emax values were noted in normal Ca
2+ buffer.  ** P 
< 0.01 compared to respective control group. 
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re 3.  A representative experiment of angiotensin II (Ang II) evoked changes in the 
 of fura-2 fluoresence (340/380 nm) in neonatal rat cardiomyocytes (NRC).  Primary 
ures of NRC loaded with fura-2 were stimulated with increasing concentrations of 
 II (10 pM – 1 µM) either in the absence (A – Control) or the presence of AA861 (10 
 B – middle panel) or MK571 (100 nM; C – lower panel).  These agents were 
tained in the cuvette in Krebs buffer (pH 7.4) containing normal Ca2+ (1.8 mM) at 
 for 3 min. prior to challenge with indicated concentration of Ang II.  Note: Each 
ple with fura-2 loaded NRC was stimulated only once with a single concentration of 
 II. 
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Figure 4.   The effects of 5-lipoxygenase (5-LO) inhibitor, AA861, and CysLT1 selective 
antagonist, MK571, on peak [Ca2+]i responses to Ang II in NRC.  Primary cultures of 
NRC were stimulated with increasing concentrations of Ang II either in the presence or in 
the absence (Control;?) of AA861 (10 µM, ∇), or MK591 (100nM; ?)  or MK571(100 
nM; ◊), or BAY u9773 (100nM, ∆) in Krebs buffer (pH 7.4) at 37oC.   Ang II 
concentration-peak [Ca2+]i responses (CR) were determined with either Ca
2+ being 
present (1.8 mM; left panel) or absent (0 mM Ca2+ + 1 mM EGTA, pH adjusted to 7.4; 
right panel) in the buffer.  Each CR curve was determined eight times using different 
batches of NRC.  *P < 0.05, **P < 0.01 compared to AA861, MK591, MK571 and Bay 
u9773 treated cells. 
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4.1.5    Effect of CysLT1 receptor antagonist, MK571, and dual CysLT1/CysLT2 
receptor antagonist, Bay u9773 on Ang II evoked increase in [Ca2+]i levels in NRC 
A representative tracing of Ang II evoked increases in fura-2 fluorescence ratio in the 
presence or absence of MK571 (100 nM) is shown (Fig 3C). The effect of CysLT1 
receptor antagonist, MK571, and dual CysLT1/ CysLT2 receptor antagonist, Bay u9773 
on Ang II evoked increase in [Ca2+]i levels in NRC is shown (Figure 4).  Addition of 
MK571 (100 nM), or Bay u9773 (100nM) led to a significant reduction in Ang II evoked 
increases in peak [Ca2+]i values (P < 0.01) in both normal and Ca
2+ free buffer. 
Although the Emax values for Ang II were relatively lower in Ca
2+ free medium, both 
MK571 and Bay u9773 evoked a higher degree of blockade (% reduction in Emax) of 
Ang II responses (right panel Figure 4).  Furthermore, in both normal and Ca2+ free 
buffer, Bay u9773 caused a higher degree of blockade of Ang II responses than MK571 
did, suggesting that both CysLT1 and CysLT2 receptor activation contribute to Ang II 
evoked increase in [Ca2+]i levels in NRC. 
4.1.6   Effects of AA861, MK591, MK571 and Bay u9773 on AVP and ET-1 evoked 
increase in [Ca2+]i levels in NRC 
 Both AVP and ET-1 evoked concentration-dependent increases in [Ca2+]i levels in NRC 
(Figure 5).  The EC50 and Emax values are summarized in Table 3.  High concentration 
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of either AA861 (30 µM), or MK591 (100nM), or MK571 (100 nM) failed to affect the 
concentration-peak [Ca2+]i response curves to AVP or ET-1 (Figure 5). 
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Figure 5. The effects of 5-lipoxygenase (5-LO) inhibitor, AA861, CysLT1 selective 
antagonist, MK571, and dual CysLT1 / CysLT2 antagonist, Bay u9773 on peak [Ca2+]i 
responses to AVP (Left panel) and ET-1 (Right panel) in NRC.  Primary cultures of NRC 
were stimulated with increasing concentrations of AVP or ET-1 either in the presence or 
in the absence (Control; ?) of AA861 (30 µM; ◊), or MK571 (100 nM; ?), or Bay 
u9773 (100nM; ∆)  in Krebs buffer (pH 7.4) at 37oC. AVP and ET-1 concentration-peak 
[Ca2+]i responses (CR) were determined with Ca
2+ being present (1.8 mM) in the buffer.  
Each CR curve was determined six times using different batches of NRC.   
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4.1.7 Effects of AT1 antagonist, losartan, AT2 antagonist, PD123319, and InsP3 
antagonist, 2APB on Ang II evoked increase in [Ca2+]i levels in NRC 
In both normal and Ca2+ free buffer, the AT1 selective antagonist, losartan, abolished the 
responses to Ang II, whereas PD123319 had no effect on Ang II evoked peak [Ca2+]i 
responses (Figure 6 ). Moreover, the InsP3 blocker, 2-APB, significantly attenuated Ang 
II evoked peak [Ca2+]i responses in both normal and Ca
2+ free buffer (Figure 6). 
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Figure 6.   The effects of AT1 receptor antagonist, losartan, AT2 receptor antagonist, 
PD123319, and InsP3 receptor antagonist, 2-APB on peak [Ca2+]i responses to Ang II in 
NRC. NRC were stimulated with increasing concentrations of Ang II either in the 
absence (Control; ?) or in the presence of losartan (1.0 µM; ◊), or PD123319 (1.0 µM; 
∇), or 2APB (5 µM; ∆) in Krebs buffer (pH 7.4) at 37oC. Ang II concentration-peak 
[Ca2+]i responses (CR) were determined with Ca
2+ being present (1.8 mM, left panel) or 
absent (0 mM, right panel) in the buffer.  Each CR curve was determined eight times 
using different batches of NRC. **P < 0.01 compared to the losartan and 2-APB treated 
cells. 
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4.1.8 Both LTD4 and LTC4 evoked concentration-dependent increase in [Ca
2+]i 
levels in NRC 
A representative tracing of Ang II, LTD4 and LTC4 evoked [Ca
2+]i response is shown 
(Figure 7). In both normal and Ca2+ free buffer, both LTC4 and LTD4 evoked rapid 
increases in peak [Ca2+]i levels (Emax: LTD4>>LTC4) with a similar time course but 
much lower Emax in comparison to Ang II. The peak responses were attained at 40, 43 
and 47 seconds after the addition of Ang II, LTD4 and LTC4 respectively (Figure 7). The 
plateau phase that sustained at levels slightly above their respective baseline values were 
reached between 120 and 180 seconds after the addition of respective agonist(s).  There 
were no significant differences between them (Figure 7). The Emax values for both LTD4 
and LTC4 in normal Ca
2+ buffer were not significantly different from the ones observed 
in Ca2+ free buffer (Table 4 & Figure 8 & 9).  
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Table 4. Analyses of LTD4 (10 pM – 10 µM) and LTC4 (10 pM – 10 µM) evoked 
increases in [Ca2+]i  either in the presence or absence of the CysLT1 selective antagonist, 
MK571 (100 nM), or the dual CysLT antagonist, Bay u9773 (100 nM),  in adherent NRC 
maintained at  37oC.  
Agonist                                 EC50                        Emax  
 (nM)   (nM) 
LTD4  
Control                          17.0 ± 4.5   217 ± 18  
MK571 (100 nM)     37.3 ± 5.6*    52 ± 11** 
Bay u9773 (100 nM)              57.5 ± 7.4*    17 ± 7** 
LTC4    
Control                          49.8 ± 16.5  107 ± 10  
MK571 (100 nM)    42.6 ± 17.3    95 ± 12 
Bay u9773 (100 nM)               63.8 ±  6.2    21 ±  9** 
  
Values shown are means ± SE of six experiments.  The basal level of [Ca2+]i in the 
absence of either LTD4 or LTC4 stimulation was 90 ± 12 nM.   MK571 or Bay u9773 was 
added 3 min prior to the addition of agonist to the cuvette. * P < 0.05, ** P < 0.01 
compared to respective control groups.   
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Figure  7.  A representative experiment of Ang II, LTD4 and LTC4 evoked changes in the 
ratio of fura-2 fluoresence (340/380nm) in NRC.  Primary cultures of NRC loaded with 
fura-2 were stimulated with either Ang II (100 nM), or LTD4 (100 nM) or LTC4 (100 
nM).  These agents were added to the cuvette in Krebs buffer (pH 7.4) containing normal 
Ca2+ (1.8 mM) at 37oC. Note: Each sample containing fura-2 loaded NRC was 
stimulated only once with a single agonist. 
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Figure  8.   The effects of CysLT1 selective antagonist, MK571, dual CysLT1 / CysLT2 
antagonist, Bay u9773, and InsP3 receptor antagonist, 2-APB on peak [Ca2+]i responses 
to LTD4 in NRC. NRC were stimulated with increasing concentrations of LTD4 either in 
the absence (Control;?) or in the presence of MK571 (100 nM; ?), or Bay u9773 (100 
nM; ?), or 2-APB (5 µM; ∆) in Krebs buffer (pH 7.4) at 37oC. LTD4 concentration-peak 
[Ca2+]i responses (CR) were determined with Ca
2+ being present (1.8 mM, left panel) or 
absent (0 mM Ca2++ 1.0 mM EGTA, right panel) in the buffer.  Each CR curve was 
determined six to eight times using different batches of NRC. **P < 0.01 compared to the 
MK571, Bay u9773 and 2-APB treated cells group. 
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Figure 9.  The effects of CysLT1 selective antagonist, MK571, dual CysLT1 / CysLT2 
antagonist, Bay u9773, and InsP3 receptor antagonist, 2-APB on peak [Ca2+]i responses 
to LTC4 in NRC. NRC were stimulated with increasing concentrations of LTC4 either in 
the absence (Control;?) or in the presence of MK571(100 nM; ?), or Bay u9773 (100 
nM; ?), or 2-APB (5 µM; ∆) in Krebs buffer (pH 7.4) at 37oC. LTC4 concentration-peak 
[Ca2+]i responses (CR) were determined with Ca
2+ being present (1.8 mM, left panel) or 
absent (0 mM Ca2+ + 1.0 mM EGTA, right panel) in the buffer.  Each CR curve was 
determined six to eight times using different batches of NRC. **P < 0.01 compared to the 
Bay u9773 and 2-APB treated cells group. 
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4.1.9  Effect of CysLT1 receptor antagonist, MK571, dual CysLT1/CysLT2 receptor 
antagonist, Bay u9773, and InsP3 receptor antagonist, 2-APB on both LTD4 and 
LTC4 evoked increase in [Ca
2+]i levels in NRC 
Inclusion of CysLT1 receptor antagonist, MK571, significantly decreased the Emax and 
increased the EC50 value for LTD4, but it failed to evoke a significant reduction in the 
weak [Ca2+]i signals evoked by LTC4 in either normal or Ca
2+ free buffer (Figure 8 & 
9). However, inclusion of Bay u9773 abolished both LTD4 and LTC4 evoked [Ca
2+]i 
response in either normal or Ca2+ free buffer (Figure 8 & 9). The analysis of data 
obtained from several CR curves is summarized in Table 4.  Furthermore, the InsP3 
blocker, 2-APB, completely blocked both LTD4 and LTC4 evoked peak [Ca
2+]i responses 
in both normal and Ca2+ free buffer (Figure 8 & 9). 
 
4.1.10     Effect of 5-LO inhibitor, AA861, and CysLT1 antagonist, MK571 on Ang II 
evoked increase in [Ca2+]i levels in single NRC  
Single cell Ca2+ imaging studies revealed qualitatively similar results.  A typical 
experiment performed with Ang II stimulation (50 nM) on three different coverslips 
loaded with fura-2 on the same day using the same batch of cardiomyocytes is shown 
(Figure 10).  Basal fluorescence levels prior to stimulation are shown in the top panel 
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[control – (A), AA861 – (B), MK571 - (C)].  The lower panel shows the effect of Ang II 
at 30 seconds in the presence of either AA861 (E) or MK571 (F).  The responses are 
compared with images determined for Ang II in the absence of these interacting agents 
[control – (D)].  Single cell fluorescence determination from several experiments (n = 5) 
gave the following absolute [Ca2+]i values: control - 585 ± 34 nM; AA861 - 400 ± 27 nM 
(P < 0.01); MK571 - 460 ± 21 nM (P < 0.01).  Although single cell Emax values for Ang 
II were higher when compared to data obtained with multiple cells, a similar pattern of 
blockade in the presence of AA861 or MK571 was evident.  Between 2 and 3 min 
intervals the cells had reached steady state fluorescence close to the basal value 
suggesting the fluorescence changes are consistent with [Ca2+]i changes and that the 
results gathered were not due to photobleaching (data not shown).  
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Figure 10.  Fura-2 Ca2+ imaging in single neonatal rat cardiomyocyte stimulated with 
Ang II (50 nM).  Ca2+ images were acquired at a rate of 3 images per second, using three 
different coverslips loaded with fura-2 under identical conditions on the same day.  The 
upper panels (A, B, C) depicts basal fura-2 fluorescence images (340/380 nm excitation 
ratio) acquired before the addition of Ang II in the absence (A) or the presence of AA861 
(B) or MK571 (C).  The lower panels show changes in fura-2 fluorescence at 30 seconds 
after the addition of Ang II in the same cells (D – Ang II alone; E - Ang II in the presence 
of AA861, 10 µM; F - Ang II in the presence of MK571, 100 nM).  The aggregate 
[Ca2+]i values in single cells obtained were (nM): A -110; B -124, C - 117; D - 710; E - 
470; F - 530).  At the end of two min. the fluorescence values were less than 200 nM in 
all the cells (data not shown).  Similar response patterns were recorded in five separate 
experiments.  
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 4.1.11     Effects of Ang II, AVP and ET-1 on total CysLTs production in NRC 
The basal CysLT level in the culture medium was 9.7 ± 1.9 pg/2h/106 cells.  Addition of 
Ang II led to a rapid, time-dependent increase in CysLT level reaching a maximum (19.8 
± 2.6 pg/ml/106 cells) at 1 min remained at the same level until 5 min and gradually 
decreased thereafter.  However, the increases in CysLT levels were significantly higher 
(15.7 ± 1.8 pg/ml/106 cells) even 30 seconds after the addition of Ang II (Figure 11).  In 
contrast, neither AVP (100nM) nor ET-1 (100 nM) evoked a time–dependent increase in 
CysLT levels (Figure 11). 
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Figure 11.  The time dependence of Ang II evoked increases in CysLT levels in the 
culture medium of NRC. Total CysLT levels in the medium at different time points 
following stimulation with a fixed concentration of Ang II (100 nM;?), AVP (100 nM; 
?) and ET-1(100 nM; ?) were shown. Each curve was determined five times using 
different batches of NRC.  
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4.1.12    Effects of AA861, MK591, losartan and PD123319 on Ang II evoked total 
CysLTs production  
The CR determinations for CysLT generation revealed that the Ang II effect was also 
concentration-dependent (Figure 12).  The Emax for Ang II (100 nM) evoked CysLT 
release was two fold higher than the basal level.  In contrast to Ang II, addition of 
increasing concentration of either ET-1 or AVP failed to evoke a significant increase in 
CysLT production (Figure 12). Inclusion of losartan, or AA861, or MK591 abolished 
Ang II-evoked total CysLT release into the culture medium whereas addition of 
PD123319 failed to affect Ang II evoked increases in CysLT production (Figure 12).  
None of the antagonists or inhibitors affected the basal total CysLT generation. CysLT 
generation was significantly higher at 30 seconds and the peak [Ca2+]i increase was 
reached at 40 seconds after the addition of Ang II (100 nM) suggesting that the increased 
CysLT generation evoked by Ang II may contribute to elevation in [Ca2+]i (Figure 7 and 
Figure 11).  
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Figure 12.   The effects of losartan, PD123319 and AA861 on Ang II–evoked increases 
in CysLT levels and the lack of effect of ET-1 and AVP on CysLT production in NRC.  
Line graphs provide a comparison of elevation in total CysLT levels attained in the 
medium one min. after stimulation with increasing concentrations of Ang II either in the 
presence or in the absence (Control: Ang II alone; ?) of losartan (1 µM; ?), PD123319 
(1 µM; σ), or AA861 (10 µM; ∆).   Moreover, the lack of significant changes in CysLT 
levels in the medium 1 min after stimulation with increasing concentrations of either 
AVP or ET-1 are also shown. Each curve was determined five times using different 
batches of NRC. ** P < 0.01 compared with losartan, AA861, AVP, and ET-1 treated 
cells.
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4.1.13    CysLT1  and  CysLT2 receptor mRNA expression in NRC 
Both CysLT1 and CysLT2 receptor mRNA was detected in NRC by northern 
hybridization analysis (Figure 13). It appeared that the mRNA of CysLT1  was more 
abundantly expressed in NRC than that of CysLT2. However, the precise quantilation for 
the expression of CysLT1 and CysLT2 need to be determined by employing other 
experimental methods.  
 
         
NRC  Spleen              NRC    Spleen 
                              
Figure 13.   CysLT1 and CysLT2 mRNA expression in primary cultures of NRC. Spleen   
ß Actin(2.1kb) ß Actin 
CysLT2 (~1kb) CysLT1(~1kb) 
total RNA isolated from SD rats was used as a positive control.  
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4. 2 Results from Studies Using ASMC 
4.2.1 Aortic smooth muscle cells    
After initial isolation, the time required for ASMC to reach confluency in the flask varied 
from 6 to 8 days.  ASMC were allowed to proliferate due to the presence of L-glutamine, 
horse serum, and newborn calf serum in the incubation medium. ASMC grew in a 
characteristic ‘Hill and Valley’ pattern, with the valleys representing the monolayer of 
cells. Individual ASMC are spindle shaped and they differ from fibroblasts in that they 
have only one or two nucleoli present in the nucleus while fibroblasts have four or five. 
Although cobble-shaped EC’s are common contaminants of the culture, care was taken to 
ensure the meticulous removal of these cells during the initial isolation as well as during 
the period of initial growth before the cells attained confluency. Although ASMC could 
be more adequately characterized with the routine use of anti- α-actin or anti-myosin 
antibodies, the above procedure was used to obtain ASMC cultures with high purity.  The 
efficacy of this technique was verified with occasional antibody studies. Viability of cells 
was repeatedly monitored using the trypan blue exclusion test, whereby dead or dying 
cells take up the blue dye, while healthy cells remain intact. Viability of cells was 
consistently greater than 90%. ASMC viewed under a microscope on both low and high 
power are shown in Figure14.   
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Figure 14. Aortic smooth muscle cells (ASMC) when viewed under a microscope at (a) 
x 10 and (b) x 40 magnification.  Spindle shaped ASMC have one or two nucleoli-clearly 
observed at the higher magnification. 
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4.2.2 Basal systolic blood pressures(SBP) and basal   [Ca2+]i levels in ASMC of 
WKY and SHR 
Prior to the experiments, SBP of SHR and WKY rats were measured using rat tail cuff 
using BP monitor/amplifier and rat tail occluder cuff (Harvard Apparatus, St Laurent, 
Quebec). The baseline SBP before the isolation of ASMC was 112± 7 mmHg and 166 ± 
8 mmHg in WKY and SHR (n=17 for each strain, p<0.01) respectively. The basal [Ca2+]i 
levels in normal Ca2+ buffer were (nM) 97 ± 12 (WKY), 135 ± 13 (SHR) in multiple 
cells (n=26) and 106 ± 12 nM (WKY), 148 ± 16 nM (SHR) in single cells  (n=18) (Table 
2). The differences in basal [Ca2+]i levels observed by both methods were not significant. 
None of the antagonists or inhibitors affected the basal [Ca2+]i levels in either strains. 
 
4.2.3   Effects of 5-LO inhibitor, AA861, and FLAP inhibitor, MK591 on Ang II 
evoked increase in [Ca2+]i levels in ASMC of WKY and SHR 
A representative tracing of Ang II evoked increases in fura-2 fluorescence ratio in the 
presence or absence of MK591 (100 nM) is shown (Figure 15). In both WKY and SHR, 
Ang II (100 nM) evoked a rapid concentration-dependent increase in the ratio of fura-2 
fluorescence with maximal increases observed around 45 seconds that was followed by a 
decrease till reaching a steady state above the basal level at 2 min after stimulation 
(Figure 15). The Emax values for Ang II evoked increases in [Ca
2+]i in ASMC were 
significant higher in SHR than that in WKY (Table 5). In normal Ca2+ (1.8 mM) buffer, 
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either AA861 (10 µM), or MK591 (100nM) significantly reduced Ang II evoked 
increases in peak [Ca2+]i values in both WKY (P < 0.05) and SHR (P < 0.01). The 
reduction in Ang II evoked responses (both the magnitude of the responses and the % 
reduction in Emax reductions) were more pronounced in SHR (WKY 12-18%; SHR 25-
39%) as shown (Figure 16 & Table 5).  Similar effects were observed in Ca2+ free buffer, 
except the lower Emax values for Ang II and higher percentage reduction in Emax values 
(WKY 17-24%; SHR 34-49%) (Figure 17 & Table 5).  Both AA861 and MK591 evoked 
similar degree of blockade of Ang II responses.  Neither AA861 nor MK591 affected the 
basal fura-2 fluorescence and the time courses for either agonist to evoke the peak 
response or recovering to the steady state level (Figure 15). Moreover, none of them led 
to a significant change in EC50 values for Ang II. 
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Table 5.  Analyses of angiotensin II (Ang II, 1 µM), endothelin-1 (ET-1, 100 nM) and 
AVP (1 µM) evoked increases in [Ca2+]i either in the presence or in the absence of the 
different inhibitors in ASMC form WKY and SHR.  
 
                                      WKY              SHR                                        WKY                      SHR 
                                            [Ca2+]e1.8 mM ____                      [Ca2+ ]e 0 mM + 1.0 mM EGTA____      
Agonist        EC50 (nM)    Emax (nM)    EC50 (nM)    Emax (nM)         EC50 (nM)   Emax (nM)     EC50 (nM)   Emax (nM) 
Ang II 
Control          19 ± 3         445 ± 32       21 ± 4       615 ± 34^^          17 ± 3        220 ± 15        22  ± 4      315 ± 24^^ 
AA861          20 ±  5        368 ± 25*     22 ± 4       375 ± 29**          16  ± 4       163 ± 13*       23 ± 5      167 ± 15** 
MK571         22 ± 3         393 ±29        20 ± 4       460 ± 28**          17  ± 3       180 ± 13*       22 ± 4       210 ± 20** 
Bay u9773    19 ± 5         365 ± 27*     23 ± 5       383 ± 30**          19 ± 4        165 ± 14*       20 ± 5      163 ± 17** 
MK591         20 ± 4         370 ± 27*     24 ± 5       390 ± 19**           19 ± 4        170 ± 16*      18 ± 5       182 ± 18** 
Losartan          ND               41 ± 10*        ND          55 ± 11**            ND              24 ± 10*        ND           32 ± 8** 
PD123319       22 ± 4         415 ± 32      16 ± 54     592 ± 32               32 ± 6         210 ± 15       16 ± 54      308 ± 26 
2-APB             23 ± 4         198 ± 23*     21 ± 3       256 ± 24**           17 ± 3          87 ± 11*      25 ± 3        113 ± 11** 
ET-1 
Control            7 ± 1          232 ± 21        5 ± 2         326 ± 26  
AA861             7 ± 2         245 ± 25        5 ± 2          342 ± 31 
MK571            8± 2         256 ± 24        5 ± 2          353 ± 28 
Bay u9773       9 ± 2         216 ± 23        6 ± 1          347 ± 29 
AVP 
Control             24 ± 2         210 ± 18        27 ± 2       303 ± 24                 
AA861             27 ± 3         200 ± 20        25 ± 4      293 ± 28 
MK571            23 ± 2         225 ± 22        25 ± 4       315 ± 28 
Bay u9773       25 ± 2         220 ± 21        32 ± 5       306 ± 27 
______________________________________________________________________ 
 
Values shown are mean ± SEM of six experiments.  The basal levels of cytosolic Ca2+ 
concentration ([Ca2+]i) of ASMC in the absence of agonist stimulation were 97 ± 12 nM 
and 135 ± 13 nM for WKY and SHR respectively. Either AA861 (10 µM), or MK591 (10  
nM), or MK571 (100 nM), or Bay u9773(100 nM) were added for 3 min prior to the 
addition of agonist.   * P <0.05, ** P < 0.01 compared to respective control group in the 
same strain rats. ** P < 0.01 compared to the control of WKY strain.   
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Figure 15.   A representative experiment of Ang II evoked changes in the ratio of fura-2 fluoresence (340/380nm) in ASMC of WKY 
(left 4 tracings) and SHR (right 4 tracings) rats. ASMC loaded with fura-2 were stimulated with Ang II (100 nM) in the absent 
(Control) or in the present of either MK571 (100 nM), or Bay U9773 (100 nM) or AA861 (10 µM). These agents were added to the 
cuvette for 5 min. prior to the inclusion of Ang II in Krebs buffer (pH 7.4) containing normal Ca2+ (1.8 mM) at 37oC. Note: Each 
sample containing fura-2 loaded ASMC was stimulated only once with a single agonist. 
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Figure 16.   The effects of AA861, MK591, MK571, and Bay u9773 on peak [Ca2+]i 
responses to Ang II in ASMC (2nd –5th passage) in the normal Ca2+ buffer. ASMC were 
stimulated with increasing concentrations of Ang II either in the absence (Control; ?) or 
in the presence of AA861 (10 µM; ∇), or MK571 (100 nM; •), or MK591 (100nM; ∆) or 
Bay u9773 (100nM; ?) in Krebs buffer (pH 7.4) at 37oC.  Ang II concentration-peak 
[Ca2+]i responses (CR) were determined with Ca
2+ being present (1.8 mM) in the buffer.  
Each CR curve was determined eight times using different batches of ASMC.  *P < 0.05, 
**P < 0.01 compared with the MK571, AA861, MK591 and Bay u9773 treated group. 
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Figure 17.  The effects of 5-LO inhibitor, AA861, FLAP inhibitor, MK591, CysLT1 
selective antagonist, MK571, and dual CysLT1 / CysLT2 antagonist, Bay u9773 on peak 
[Ca2+]i responses to Ang II in ASMC (2
nd –5th passage) in the Ca2+ free buffer. ASMC 
were stimulated with increasing concentrations of Ang II either in the absence 
(Control;?) or in the presence of AA861 (10 µM; ∇), or MK571 (100 nM; •), or MK591 
(100nM; ∆) or Bay u9773 (100nM; ?) in Krebs buffer (pH 7.4)  at 37oC.   Ang II 
concentration-peak [Ca2+]i responses (CR) were determined with Ca
2+ being absent in 
the buffer.  Each CR curve was determined eight times using different batches of ASMC.  
*P < 0.05, **P < 0.01 compared with the MK571, AA861, MK591 and Bay u9773 
treated group. 
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4.2.4 Effects of CysLT1 receptor antagonist, MK571, and dual CysLT1/CysLT2 
receptor antagonist, Bay u9773 on Ang II evoked increase in [Ca2+]i levels in ASMC  
A representative tracing of Ang II evoked increases in fura-2 fluorescence ratio in the 
presence or absence of Bay u9773 (100 nM) is shown (Figure 15). In normal Ca2+ (1.8 
mM) buffer, either MK571 (100 nM), or Bay u9773 (100 nM) significantly reduced Ang 
II evoked increases in peak [Ca2+]i values in both WKY (P < 0.01) and SHR (P < 0.01) 
(Figure 16). The reductions in Ang II evoked responses (both the magnitude of responses 
and the % reduction in Emax) were more pronounced in SHR (WKY 12-18%; SHR 25-
39%)(Figure 16 & Table 5).  In both WKY and SHR, inhbition of responses was 
observed in Ca2+ free buffer.  However, the Emax values for Ang II evoked responses 
were relatively lower and the percentage reduction in Emax values (compared with that 
obtained in normal Ca2+ buffer) attained by inclusion of these CysLT antagonists were 
relatively higher in Ca2+ free buffer  (WKY 17-24%; SHR 34-49%) (Figure 17 & Table 
5).  More importantly, MK571 evoked blockade of peak [Ca2+]i responses to Ang II was 
relatively lower compared to the responses seen in the presence of Bay u9773, in both 
normal and Ca2+ free buffer (Figure 16, 17 & Table 5).  
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4.2.5   Effects of AA 861, MK591, MK571 and Bay u9773 on AVP and ET-1 evoked 
increase in [Ca2+]i levels in ASMC  
Both AVP and ET-1 evoked concentration-dependent increases in [Ca2+]i levels in 
ASMC of WKY and SHR (Figure 18 & 19).  The Emax values for both AVP and ET-1 
were higher in SHR than that in WKY. The EC50 and Emax values are summarized in 
Table 5.   In the normal Ca2+ buffer, high concentration of either AA861 (30 µM), or 
MK591 (100 nM), or MK571 (100 nM) failed to affect the concentration-peak [Ca2+]i 
response curves to AVP or ET-1 in ASMC of WKY and SHR (Figure 18 & 19). 
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Figure 18. The effects of 5-lipoxygenase inhibitor, AA861, CysLT1 selective antagonist, 
MK571, and dual CysLT1 / CysLT2 antagonist, Bay u9773 on peak [Ca2+]i responses to 
AVP in ASMC in the normal Ca2+ buffer. ASMC (2nd – 5th passages) were stimulated 
with increasing concentrations of AVP either in the presence or in the absence (Control; 
?) of AA861 (30 µM; •), or  MK571 (100 nM; ?), or Bay u9773 (100nM; ∆)  in Krebs 
buffer (pH 7.4) at 37oC. AVP concentration-peak [Ca2+]i responses (CR) were 
determined with Ca2+ (1.8 mM) being present in the buffer.  Each CR curve was 
determined six times using different batches of ASMC.   
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Figure 19.  The effects of 5-lipoxygenase (5-LO) inhibitor, AA861, CysLT1 selective 
antagonist, MK571, and dual CysLT1 / CysLT2 antagonist, Bay u9773 on peak [Ca2+]i 
responses to ET-1 in ASMC in the normal Ca2+ buffer. ASMC (2nd – 5th passages) were 
stimulated with increasing concentrations of ET-1either in the presence or in the absence 
(Control; ?) of AA861 (30 µM; •), or  MK571 (100 nM; ?), or Bay u9773 (100nM; ∆) 
in Krebs buffer (pH 7.4) at 37oC. ET-1 concentration-peak [Ca2+]i responses (CR) were 
determined with Ca2+ (1.8 mM) being present in the buffer.  Each CR curve was 
determined six times using different batches of ASMC. 
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4.2.6   Effects of AT1 antagonist, losartan, AT2 antagonist, PD 123319, and InsP3 
antagonist, 2-APB on Ang II evoked increase in [Ca2+]i levels in ASMC  
The InsP3 blocker, 2-APB, and the AT1 selective antagonist, losartan significantly 
reduced the responses to Ang II, but the AT2 selective antagonist, PD123319, failed to 
block the responses to Ang II (Table 5 & Figures 20 & 21).  However, both agents failed 
to affect the EC50 values for Ang II (Table 5).  
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Figure 20.   The effects of AT1 receptor antagonist, losartan, AT2 receptor antagonist, 
PD123319, and InsP3 receptor antagonist, 2-APB on peak [Ca2+]i responses to Ang II in 
ASMC (2nd –5th passage) in the normal Ca2+ buffer. ASMC were stimulated with 
increasing concentrations of Ang II either in the absence (Control; ?) or in the presence 
of losartan (1.0 µM; •), or PD123319 (1.0 µM; ?), or 2-APB (5 µM; ∆) in Krebs buffer 
(pH 7.4) at 37oC.   Ang II concentration-peak [Ca2+]i responses (CR) were determined 
with Ca2+ being present (1.8 mM) in the buffer.  Each CR curve was determined eight 
times using different batches of ASMC. **P < 0.01 compared with 2APB- and losartan- 
treated group. 
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Figure 21.   The effects of AT1 receptor antagonist, losartan, AT2 receptor antagonist, 
PD123319, and InsP3 receptor antagonist, 2-APB on peak [Ca2+]i responses to Ang II in 
ASMC (2nd –5th passage) in the Ca2+ free buffer. ASMC were stimulated with 
increasing concentrations of Ang II either in the absence (Control; ?) or in the presence 
of losartan (1.0 µM; •), or PD123319 (1.0 µM; ?), or 2-APB (5 µM; ∆)  in Krebs buffer 
(pH 7.4) at 37oC.  Ang II concentration-peak [Ca2+]i responses (CR) were determined 
with Ca2+ being absent in the buffer.  Each CR curve was determined eight times using 
different batches of ASMC. **P < 0.01 compared with 2APB- and losartan-treated 
group. 
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4.2.7   Both LTD4 and LTC4 evoked concentration-dependent increase in [Ca
2+]i 
levels in ASMC 
A representative tracing of LTD4 and LTC4 evoked [Ca
2+]i response is shown (Figure 22, 
23 ).  In both normal and Ca2+ free buffer, LTD4 and LTC4 evoked increases in [Ca
2+]i 
levels with the peak responses attained in 30 to 45 seconds (Figure 22 & 23).  There were 
no differences in the time course of the responses evoked by LTD4 and LTC4 in ASMC 
derived from either WKY or SHR strains.  Both LTD4 and LTC4 evoked a similar degree 
of increases in peak  [Ca2+]i levels in normal Ca
2+ and Ca2+ free buffer (Figure 24, 25, 
26, 27). The Emax values for LTD4 were higher than that for LTC4, but much lower in 
comparison to the responses evoked by Ang II in the ASMC of either strain. The Emax 
values for LTD4 and LTC4 were higher in SHR (Figure 24, 25, 26, 27& Table 6). While 
Bay u9773 completely attenuated the maximal [Ca2+]i responses evoked by both LTC4 
and LTD4 in either strain, MK571 incubation led to incomplete blockade of [Ca
2+]i 
responses evoked by LTD4 (Figure 24, 25, 26, 27& Table 6). Neither MK571 nor Bay 
u9773 led to significant change in the EC50 values for LTD4 and LTC4. The InsP3 
antagonist, 2-APB, abolished the [Ca2+]i responses evoked by both LTC4 and LTD4 
(Figure 24, 25, 26, 27& Table 6).  
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Figure 22.   A representative experiment of LTD4 evoked changes in the ratio of fura-2 fluoresence (340/380nm) in ASMC of WKY 
(left 4 tracings) and SHR (right 4 tracings) rats. ASMC loaded with fura-2 were stimulated with LTD4 (1.0 µM) in the absent 
(Control) or in the present of either MK571 (100 nM), or Bay U9773 (100 nM) or 2-APB (5 µM). These agents were added to the 
cuvette for 5 min. prior to the inclusion of LTD4 in Krebs buffer (pH 7.4) containing normal Ca2+ (1.8 mM) at 37
oC. Note: Each 
sample containing fura-2 loaded ASMC was stimulated only once with a single agonist. 
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Figure 23.  A representative experiment of LTC4 evoked changes in the ratio of fura-2 fluoresence (340/380nm) in ASMC of WKY 
(left 4 tracings) and SHR (right 4 tracings) rats.  ASMC loaded with fura-2 were stimulated with LTC4 (1.0 µM) in the absent 
(Control) or in the present of either MK571 (100 nM), or Bay u9773(100 nM) or 2-APB (5 µM). These agents were added to the 
cuvette for 5 min. prior to the inclusion of LTC4 in Krebs buffer (pH 7.4) containing normal Ca2+ (1.8 mM) at 37
oC. Note:  Each 
sample containing fura-2 loaded ASMC was stimulated only once with a single agonist. 
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Table 6.  Analyses of cysteinyl leukotrienes (LTD4 and LTC4, 1 µM) evoked increases in 
[Ca2+]i either in the presence or in the absence of the different inhibitors in ASMC form 
WKY and SHR.  
 
                                      WKY                  SHR                                     WKY                        SHR 
                                            [Ca2+]e1.8 mM _________            [Ca2+ ]e 0 mM + 1.0 mM EGTA____      
Agonist        EC50 (nM)    Emax (nM)    EC50 (nM)    Emax (nM)         EC50 (nM)   Emax (nM)     EC50 (nM)   Emax (nM) 
LTD4 
Control            20 ± 5        99 ± 13         21 ± 3        181 ± 17 ^^          35 ± 5        87 ± 10           19 ± 3       171± 18^^ 
MK571            23 ± 4        55 ± 10**     24 ± 4          91 ± 11**          28 ± 4        52 ± 8*            26 ± 4       85 ±10**       
Bay  u9773      ND            18 ± 6**         ND             25 ± 9**               ND         19 ± 7**           ND           21± 5** 
2-APB           ND            23 ± 5**         ND             32 ± 9**              ND         27 ± 9**           ND          29 ± 7** 
LTC4 
Control             27 ± 4       70 ± 7          15 ± 3       116 ± 12^^           25 ± 4         62 ± 7            25 ± 4       109 ± 10^^ 
MK571             30 ± 5       58 ± 8          18 ± 3        98 ± 10                30 ± 5         54 ± 5            31 ± 5        93 ± 10 
Bay u9773          ND         16 ± 6**          ND        18 ± 6 **                ND          17 ± 5**           ND          20 ± 6** 
2-APB                  ND        22± 6**           ND        28 ± 7**                ND           21± 7**           ND          32 ± 6** 
 
Values shown are mean ± SEM of six experiments.  The basal levels of cytosolic Ca2+ 
concentration ([Ca2+]i) of ASMC in the absence of agonist stimulation were 97 ± 12 nM 
and 135 ± 13 nM for WKY and SHR respectively. Either AA861 (10µM), or MK591 (10  
nM), or MK571(100 nM), or Bay u9773(100 nM) were added for 3 min prior to the 
addition of agonist.   * P<0.05, ** P<0.01 compared to respective control group in the 
same strain rats. ** P< 0.01 compared to the control of WKY strain.   
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Figure 24.   The effects of CysLT1 selective antagonist, MK571, dual CysLT1 /CysLT2 
antagonist, Bay u9773, and InsP3 receptor antagonist, 2-APB on peak [Ca2+]i responses 
to LTD4 in ASMC (2
nd –5th passage) in the normal Ca2+ buffer. ASMC were stimulated 
with increasing concentrations of LTD4 either in the absence (Control;?) or in the 
presence of MK571 (100 nM; ◊), or Bay u9773 (100nM; ∇), or 2-APB (5 µM; ∆) in 
Krebs buffer (pH 7.4) at 37oC. LTD4 concentration-peak [Ca2+]i responses (CR) were 
determined with Ca2+ being present (1.8 mM) in the buffer.  Each CR curve was 
determined seven times using different batches of ASMC.  *P< 0.05, **P< 0.01 
compared with the MK571, Bay u9773 and 2-APB treated group. 
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Figure 25. The effects of CysLT1 selective antagonist, MK571, dual CysLT1/CysLT2 
antagonist, Bay u9773, and InsP3 receptor antagonist, 2-APB on peak [Ca2+]i responses 
to LTC4 in ASMC (2
nd –5th passage) in the normal Ca2+ buffer. ASMC were stimulated 
with increasing concentrations of LTC4 either in the absence (Control;?) or in the 
presence of MK571 (100 nM; ◊ ), or Bay u9773 (100nM; ∇), or 2-APB (5 µM; ∆) in 
Krebs buffer (pH 7.4) at 37oC. LTC4 concentration-peak [Ca2+]i responses (CR) were 
determined with Ca2+ being present (1.8 mM) in the buffer.  Each CR curve was 
determined seven times using different batches of ASMC. **P < 0.01 compared with the 
MK571, Bay u9773 and 2-APB treated group. 
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Figure 26.   The effects of CysLT1 selective antagonist, MK571, dual CysLT1/CysLT2 
antagonist, Bay u9773, and InsP3 receptor antagonist, 2-APB on peak [Ca2+]i responses 
to LTD4 in ASMC (2
nd –5th passage) in the Ca2+ free buffer. ASMC were stimulated 
with increasing concentrations of LTD4 either in the absence (Control;?) or in the 
presence of MK571 (100 nM; ◊ ), or Bay u9773 (100nM; ∇), or 2-APB (5 µM; ∆) in 
Krebs buffer (pH 7.4) at 37oC. LTD4 concentration-peak [Ca2+]i responses (CR) were 
determined with Ca2+ being absent in the buffer.  Each CR curve was determined six 
times using different batches of ASMC.  *P < 0.05, **P < 0.01 compared with the 
MK571, Bay u9773 and 2-APB-treated  groups. 
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Figure 27. The effects of CysLT1 selective antagonist, MK571, dual CysLT1/CysLT2 
antagonist, Bay u9773, and InsP3 receptor antagonist, 2-APB on peak [Ca2+]i responses 
to LTC4 in ASMC (2
nd –5th passage) in the Ca2+ free buffer. ASMC were stimulated with 
increasing concentrations of LTC4 either in the absence (Control;?) or in the presence of 
MK571 (100 nM; ◊), or Bay u9773 (100nM; ∇), or 2-APB (5 µM; ∆) in Krebs buffer (pH 
7.4) at 37oC. LTC4 concentration-peak [Ca2+]i responses (CR) were determined with 
Ca2+ being absent in the buffer.  Each CR curve was determined six times using different 
batches of ASMC. **P < 0.01 compared with the Bay u9773 and 2-APB-treated groups. 
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4.2.8 Effects of 5-LO inhibitor, AA861, and CysLT1 antagonist, MK571 on Ang II 
evoked increase in [Ca2+]i levels in single ASMC 
Single cell Ca2+ imaging studies revealed qualitatively similar results. A typical 
experiment performed with Ang II stimulation (50 nM) on adherent ASMC on four 
different coverslips loaded with fura-2 is shown (Figure 28). The data from single cell 
fluorescence determination from several experiments is summarized (Table 2).  Although 
single cell Emax values for Ang II were higher when compared to data obtained with 
multiple cells, a similar pattern of blockade in the presence of either MK591, or AA861, 
or MK571, or Bay u9773 was evident.  Between 2 and 3 min intervals the cells had 
reached steady state fluorescence close to the basal value suggesting the fluorescence 
changes are consistent with [Ca2+]i changes and that the results gathered were not due to 
photobleaching (data not shown).   
 
 
 115
WKY  SHR  
 Control                      Bay u9773                 AA861                    Control                Bay u9773                   AA861 
 
 
 
 
 
 
 
 
 
 
 
 
b 
a 
d 
ke i g
lf h j 
c 
    Ang II              Bay u9773 + Ang II   AA861 + Ang II          Ang II             Bay u9773 + Ang II    AA861 + Ang II
 
 
 
 
 116
Figure 28.  Fura-2 Ca2+ imaging in single ASMC (WKY: a, b, c, d, e, f;  SHR: g, h, i, j, k, l) stimulated with Ang II (50 nM).  Ca2+ 
images were acquired at a rate of 3 images per second, using six different coverslips loaded with fura-2 under identical conditions on 
the same day.  The upper panels (a, c, e, g, i, k) depict basal fura-2 fluorescence images (340/380 nm excitation ratio) acquired before 
the addition of Ang II in the absence (a, g) or in the presence of Bay u9773 (c, i;100 nM) or AA861 (e, k; 10 µM).  The lower panels 
show changes in fura-2 fluorescence at 30 seconds after the addition of Ang II in the same cells (b, h – Ang II alone; d,  j- Ang II in 
the presence of Bay u9773; f, l - Ang II in the presence of AA 861). At the end of two min. the fluorescence values were less than 200 
nM in all the cells (data not shown).  Similar response patterns were recorded in five separate experiments.  
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4.2.9   Effects of Ang II, AVP and ET-1 on total CysLTs production in ASMC 
The basal CysLT levels (pg/106 cells) in the culture medium were 13.2 ± 2.7 and 23.8 ± 
3.8 (P < 0.01) for WKY and SHR respectively.  Ang II but not ET-1 neither AVP evoked 
a rapid, time-dependent and concentration-dependent increases in total CysLT levels in 
either strain (Figure 29 & 30). The Emax value for Ang II was much higher in SHR (26.1 
± 4.3 vs 62.6 ± 5.8, P < 0.01), which was observed at 30 seconds after the addition of 
Ang II and remained at the same level until 5 min followed by a gradually slow decrease 
(Figure 29).  
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Figure 29.  The time dependence of Ang II- but not ET-1- neither AVP- evoked 
increases in total CysLT levels in the culture medium of ASMC of WKY (Left Panel) 
and SHR (Right Panel). The values expressed in the graph represent the total CysLT 
levels in the medium at different time points following stimulation with a fixed 
concentration of Ang II (100 nM; ?), AVP (100 nM; ∆ ) and ET-1 (100 nM; ?).  
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Figure 30.  Ang II but not ET-1 neither AVP–evoked concentration-dependent increases 
in total CysLT levels in ASMC of WKY and SHR rats.  The values expressed in the 
graph represent the total CysLT levels in the culture medium at one min. after stimulation 
with increasing concentrations of Ang II (?), ET-1(?) and AVP(∆). * P < 0.05, **P < 
0.01 compared to the respective ET-1- or AVP- treated group. # P < 0.05, ## P < 0.01 
compared to the respective WKY group. 
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4.2.10    Effects of AA861, MK591, losartan and PD123319 on Ang II evoked total 
CysLTs production in ASMC 
Either losartan, or MK591, or AA861 but not PD123319 completely blocked Ang II-
evoked total CysLT release (Figure 31). None of the inhibitors or antagonists affected the 
basal CysLT level.  CysLT generation reached maximum at 30 seconds while the peak 
[Ca2+]i increase was reached at 40 seconds after the addition of Ang II (100 nM) 
suggesting that the increased CysLT generation evoked by Ang II may contribute to 
elevation in [Ca2+]i levels (Figure 15 & 29).  
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Figure 31.   The effects of losartan, PD123319, AA861 and MK591 on Ang II–evoked 
increases in total CysLT levels in ASMC of WKY and SHR. Bar graphs provide a 
comparison of elevation in total CysLT levels attained in the medium one min. after 
stimulation with Ang II (100 nM) either in the absence (Ang II alone) or in the presence 
of losartan (1 µM), or PD123319 (1 µM), or AA861 (10 µM), or MK591 (100 nM). **P 
< 0.01 compared to the respective Basal level group. # P < 0.05, ## P < 0.01 compared to 
the respective WKY group. Basal levels represent the total CysLT levels generated by 
ASMC in 2 hours prior to the inclusion of any agonists, or antagonists, or inhibitors. 
 
 
 
 
 
 
 122
4.2.11     CysLT1  and  CysLT2 receptor mRNA expression in ASMC 
CysLT1 and CysLT2 receptor mRNAs were detected in ASMC of both strains, the 
expressions of both receptor were much higher in SHR (CysLT1 / β actin (%): 3.9 ± 0.6 
vs 16.5 ± 1.5, p<0.01; CysLT2 / β actin (%): 3.2 ± 0.6  vs  10.9 ± 1.3, p<0.01 ) (Figure 
32). 
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5. DISCUSSION 
5.1    CysLT contributes to Ang II evoked  Ca2+ signaling in NRC 
 
5.1.1.   Summary 
 
The present study provides several new observations in NRC: i) 5-LO derived 
metabolites of AA, CysLT, augment [Ca2+]i responses to Ang II in NRC. ii) Inclusion of 
5-LO inhibitor, AA861 (10 µM), or FLAP inhibitor, MK591 (100 nM) led to significant 
attenuation of Ang II but not ET-1 and AVP evoked increases in peak [Ca2+]i levels and 
CysLT release into the culture medium.  iii) Ang II evoked increases in [Ca2+]i levels 
and CysLT release in NRC are mediated by AT1 receptor activation since losartan, an 
AT1 antagonist, but not the AT2 selective antagonist, PD123319, blocked the responses 
to Ang II.  iv) Both LTD4 and LTC4 evoke [Ca
2+]i increase in these cells.  However, the 
responses to these mediators were much lower than those evoked by Ang II.  The CysLT1 
selective antagonist, MK571, significantly attenuated the [Ca2+]i responses to LTD4 but 
failed to inhibit the responses to LTC4 while the dual antagonist, Bay u9773, completely 
blocked the [Ca2+]i responses to both LTD4 and LTC4.  v) Both Ang II and CysLT 
evoked increases in [Ca2+]i levels were markedly attenuated by 2-APB, an agent that 
blocks InsP3 mediated Ca
2+ release. vi) Both CysLT1 and CysLT2 receptor mRNA were 
detected in NRC.  These data confirm that both Ang II and CysLT recruit predominantly 
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InsP3 sensitive intracellular Ca
2+ pools in NRC.  Thus, the CysLT pathway may serve as 
an additional amplifier pathway in sustaining direct AT1 mediated intracellular Ca
2+ 
mobilization evoked by Ang II in NRC.  
 
5.1.2 Ang II, AVP and ET-1 evoked increases in [Ca2+]i in NRC 
The basal levels of [Ca2+]i  obtained in the normal and free Ca
2+
 buffer in the present 
study are consistent with previous studies (Liu et al., 1999).  The basal and peak increases 
in [Ca2+]i levels were lower in the Ca
2+
  free buffer than that in the normal Ca
2+
 buffer. 
These data suggest that the Ca2+ influx contributes to the basal Ca
2+ level and Ang II 
evoked peak increases in [Ca2+]i.  The present study demonstrates that Ang II, AVP and 
ET-1 evoked concentration-dependent increases in [Ca2+]i, and that the Emax values for 
Ang II were much higher than that for AVP and ET-1.  These data are in line with the 
earlier studies (Liu et al., 1999; Xu et al., 1991 & 1993; Touyz et al., 1997b).  Several 
studies in the past have established that Ang II and AVP evoked elevations in [Ca2+]i in 
NRC stemmed predominantly from the release of Ca2+ from the intracellular stores and 
that removal of extracellular Ca2+ led to only a partial reduction in the peak increases in 
[Ca2+]i evoked by Ang II and AVP (Goldenberg et al. , 2001; Kem et al., 1991; Liu et al., 
1999; Touyz et al., 2000).  Moreover, thapsigargin, a SR Ca2+ pump inhibitor, abolished 
the [Ca2+]i response to Ang II or AVP (Kem et al., 1991; Liu et al., 1999).  Therefore, the 
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data for Ang II-evoked responses noted in either in Ca2+ free medium or the significant 
attenuation of [Ca2+]i responses to Ang II determined in the presence of 2-APB are 
consistent with the observation reported by earlier studies.  
 
5.1.3   AT1   and AT2 subtypes on NRC    
The presence of two high affinity binding sites for [125I] Ang II was demonstrated in 
membrane preparations of NRC (Rogers et al., 1986).  Each of the high affinity states of 
the Ang II receptor has been proposed to be distinctly linked to different phospholipid 
second messengers.  The AT1 subtype was suggested to promote [
3H] inositolphosphate 
accumulation via activation of PLC while the AT2 subtype was suggested to be linked to 
[3H] AA release via activation of PLA2.  However, other studies have demonstrated that 
stimulation of AT1 receptors lead to activation of PLA2 (Freeman EJ, 1998; Pueyo ME, 
1996; Bharatula M, 1998).  A few studies have also shown that Ang II induced 
alkalinization was sensitive to blockade by AT2 but not AT1 selective antagonist (Kohout 
et al., 1995; Lokuta et al., 1994).  It was also proposed that AT1 mediated hypertrophy by 
Ang II could be opposed by AT2 mediated antigrowth events in NRC (Booz et al., 1996; 
van Kesteren et al., 1997). In addition, another report showed that Ang II-induced 
apoptosis in NRC may be mediated through activation of both AT1 and AT2 receptors 
(Goldenberg et al., 2001).  In contrast to these reports, detailed characterization of AT1 
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and AT2 specific binding sites and receptor expression studies using the RT-PCR strategy 
have revealed the presence of only a single class of AT1 specific binding sites on NRC 
(Touyz et al., 1996a).  Several studies by others have also established that both the 
increases in [Ca2+]i and all phospholipid second messengers generated by Ang II in NRC 
are indeed mediated solely by the activation of AT1 and not the AT2 subtype (Kem et al., 
1991; Sadoshima et al., 1993; Touyz et al., 1996a).  Others have established that Ang II 
can also activate PLA2 and PLD leading to an elevation in AA-derived metabolites 
(Dulin et al., 1998; Lokuta et al., 1994; Nasjletti et al., 1998; Parmentier et al., 2001, Rao 
et al., 1994; Touyz et al., 2000; Zafari et al., 1999).  The present study demonstrates that 
Ang II evoked increases in CysLT and [Ca2+]i levels were abolished by losartan but not 
PD123319, suggesting a link between the AT1 and PLA2 mediated AA-derived CysLT 
production and PLC/InsP3 mediated Ca
2+ signaling events in NRC. This result is 
consistent with the previous studies (Freeman et al., 1998; Pueyo et al., 1996; Bharatula 
et al., 1998).  Therefore AT1 receptor activation and the resultant PLC/InsP3 mediated 
[Ca
2+
]i responses may also be partly mediated by AA-derived CysLT production in 
NRC.  However, more studies using PLA2 inhibitors and their effects on Ang II evoked 
changes in CysLT production appear prudent in the future to resolve these issues.  
Receptor binding methods were not employed in the present study as the focus of the 
present study was to examine the involvement of CysLT in the Ang II-mediated elevation 
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in peak [Ca
2+
]i responses and to explore which Ang II receptor subtype mediated CysLT 
generation.  Based on the data of the present study, a conclusion of the existence of only 
AT1 subtype in NRC could be reached.  
 
5.1.4   Ang II - CysLT Interaction 
Ang II is known to activate both cytosolic and membrane bound PLA2 in various tissues 
including cardiomyocytes that resuls in the release of AA and formation of its vasoactive 
metabolites (Nasjletti, 1998; Rao GN, 1994; Touyz et al., 2000; Amadou et al., 2002; 
Chen et al., 1998).  Earlier studies have shown that Ang II-evoked vascular hypertrophy 
may be at least partially mediated by non-cycloxygenase derived AA metabolites (Dulin 
et al., 1998; Parmentier et al., 2001; Zafari et al., 1999).  Recently, studies have shown 
that the 5-LO inhibitor, AA861, or the CysLT1 antagonist, MK571 reduced the 
vasoconstrictor responses to Ang II suggesting that CysLT generation and subsequent 
CysLT1 receptor activation may mediate vasoconstriction to Ang II (Shastri et al., 2001; 
Stanke-Labesque et al., 2001).  It is well established that both Ang II and CysLT are 
coupled to Ca2+ signaling (Touyz et al., 2000; Lynch et al., 1999; Heise et al., 2000). 
Therefore, it was important to provide direct evidence at the level of signal transduction 
for a link between Ang II, AT1 receptor activation, CysLT generation and CysLT 
receptor mediated alterations in [Ca2+]i levels.  It is well known that cell surface 
receptors for ET-1 are several orders of magnitude higher than the receptors for Ang II in 
NRC (Booz et al., 1996).  Previously, we have shown that Ang II evoked much greater 
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increases in [Ca2+]i than both AVP and ET-1 in NRC (Xu et al., 1991; Xu et al., 1993).  
These data suggested that additional mechanisms and signal transduction events likely 
account for the much greater increases in [Ca2+]i responses to Ang II.  The present data 
confirms that Ang II increased CysLT generation via AT1 receptor activation, which in 
turn augments the [Ca2+]i response to Ang II.  In contrast, AVP and ET-1 evoked 
increases in [Ca
2+
]i levels were not reduced by the inclusion of either AA861 or MK571.  
Moreover, both ET-1 and AVP failed to promote CysLT production, suggesting that only 
Ang II promotes CysLT production via AT1 receptor activation.  This is consistent with 
the view that Ang II is a pleiotropic agonist that recruits multiple signaling pathways to 
account for its potential role in the regulation of cardiovascular function (Touyz et al., 
2000).  Previously, others have confirmed that Ang II-evoked increases in [Ca2+]i might 
play a more important role than protein kinase C (PKC) activation in hypertrophic 
responses to Ang II in NRC (Sadoshima et al., 1995a & 1995b).  The present study 
demonstrates consistency in the time course response for the CysLT generation and the 
subsequent Ca2+ increase, suggesting that CysLT generation evoked by Ang II may serve 
as an additional amplifier pathway in sustaining direct AT1 mediated Ca
2+ mobilization 
in NRC. Thus, the present study provides a possible explanation for the higher Emax to 
Ang II.  Furthermore, studies have already demonstrated that the increases in [Ca2+]i 
plays a crucial role in Ang II evoked hypertrophy in NRC (Sadoshima et al., 1995 a & b).  
 
 
 130
The observation from the present study suggests that CysLT may contribute to Ang II–
evoked contractility and/or hypertrophy in cardiomyocytes.  More studies on the direct 
effects of CysLT on the DNA and protein synthesis in NRC would provide the direct 
evidence for the hypertropic effect of CysLT. 
 
 5.1.5  CysLT and Ca
2+
 Signaling   
Although evidence that Ang II increases CysLT generation via AT1 receptor activation 
was provided by the present study, it is important to demonstrate that CysLT contributes 
to Ca2+ mobilization in NRC.  There are no studies suggesting the presence of CysLT 
receptors in NRC.  In human detrusor smooth muscle cells, it was reported that elevation 
in [Ca2+]i levels evoked by LTD4 were almost exclusively due to mobilization from 
intracellular Ca2+ stores (Bouchelouche et al., 2001 &  2003). In other target cells, the 
LTD4 evoked Ca
2+ response was dependent on the release of Ca2+ from intracellular 
stores and enhanced Ca2+ influx (Ochsner et al., 1996; Pedersen et al., 1997).  The 
present study demonstrates that both Ang II and CysLT evoked increases in [Ca2+]i 
levels were significantly attenuated by 2-APB.  In addition, both AA861 and MK571 
caused a similar degree of blockade of Ang II response in normal as well as Ca2+ free 
buffer.  Thus, this is the first report to characterize CysLT evoked increase in [Ca2+]i that 
may be mainly due to the release of Ca
2+
 from InsP3 sensitive intracellular SR Ca
2+ 
pools in the NRC.  
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5.1.6   CysLT Receptors in NRC 
   The human CysLT1 and CysLT2 receptors have been cloned and characterized only in 
the recent years (Heise et al., 2000; Lynch et al., 1999). With the use of a variety of 
techniques including in situ hybridization, Northern blotting, and RT-PCR, the presence 
of CysLT1 and/or CysLT2 transcripts in cardiac tissue has been identified (Heise et al., 
2000; Kamohara et al., 2001; Lynch et al., 1999; Ogasawara et al., 2002). Consistent with 
this observation, we have noted that both LTD4 (MK571 sensitive) and LTC4 (MK571 
resistant) evoke concentration-dependent [Ca2+]i responses in NRC.   Moreover, addition 
of Bay u9773 completely blocked both LTD4 and LTC4 evoked [Ca
2+]i responses. More 
importantly, both CysLT1 and CysLT2 receptor mRNA was detected by northern 
hybridization analysis.  These data suggest that NRC may possess both CysLT1 and 
CysLT2 specific binding sites that are linked to Ca
2+ mobilization.  Previously, it was 
reported that the affinity of LTC4 for CysLT1 receptor was roughly 10 to 350 folds lower 
than that of LTD4 (Heise et al., 2000; Lynch et al., 1999).  Overall, the rank order of 
affinities of the CysLT for the CysLT1R and CysLT2R is LTD4>>LTC4>LTE4 and 
LTD4=LTC4>>LTE4 respectively (Heise et al., 2000, Maekawa et al., 2002).  Our study 
demonstrates that LTD4 induced a stronger [Ca
2+]i response than LTC4 and that Bay 
u9773 but not MK571 blocked LTC4 induced [Ca
2+]i responses.  It is likely that LTD4 
evoked responses are mediated by both CysLT1 and CysLT2 receptors while it is likely 
that LTC4 interacts at CysLT2 receptors on NRC that are insensitive to blockade by 
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MK571.  These observations are consistent with the earlier findings that [3H] LTC4 
specific binding to human lung tissues could not be displaced at concentration ranges up 
to 3 µM by either CysLT1 antagonists (zafirlukast, and montelukast) or LTD4 (Aharony, 
1998; Heise et al., 2000; Lynch et al., 1999).  Moreover, zafirlukast resistant contractile 
responses to LTC4 were observed in guinea pig trachea when LTC4 metabolism to LTD4 
was prevented (Aharony, 1998).  In CysLT2-expressing clones, such as CHO-7A, CHO-
8B3 and PC12 cells, both LTC4 and LTD4 exhibited dose-dependent increases in [Ca
2+]i 
levels that were sensitive to blockade by Bay u9773 (Ogasawara et al., 2002). The 
peritoneal macrophages (that express both CysLT1 and CysLT2 receptors) responded 
substantially to LTD4 (1 µM) and only slightly to 1 µM of LTC4 (Maekawa et al., 2002).  
All these studies together with our present data using NRC support the notion that LTD4 
evoked [Ca2+]i responses may be mediated by both CysLT1 and CysLT2 receptors while 
the weaker [Ca2+]i response evoked by LTC4 may be mediated by CysLT2 receptors.   
 
5.1.7   Effects of CysLT on NRC 
    Although several studies have suggested that CysLT evoke negative inotropic effects, 
this has been attributed to profound coronary vasoconstriction mediated by CysLT2 
receptors located on coronary arteries (Kamohara et al., 2001). Consistent with this, both 
LTD4 and LTC4 at low concentrations have been shown to exert a positive inotropic 
effect on the rat myocardium and that Ang II infusion has been shown to enhance LTA4 
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hydrolase activity in the rat heart (Ishisaka et al., 1999; Karmazyn et al., 1990).  These 
findings support our observation of elevated [Ca2+]i levels evoked by CysLT in NRC. 
Althogh the effect of CysLTs on the DNA and protein synthesis was not examined in the 
present study, in fact, the elevation in [Ca2+]i level has been suggested to play a more 
critical role than PKC activation towards hypertrophy evoked by Ang II in NRC 
(Sadoshima et al., 1993; Sadoshima et al., 1995 a & b).  Taken together with our new 
findings, these data provide the impetus for a more detailed characterization of the 
interactions between Ang II, CysLT generation and CysLT receptor mediated increase in 
Ca2+ mobilization and their relative roles and contribution to cardiac hypertrophy. 
 
5.2.  CysLT Contributes to the Exaggerated Ang II Evoked Ca2+ 
Signaling in ASMC from SHR  
 
 
5.2.1.   Key Findings 
Firstly, the present study demonstrates for the first time that either 5-LO inhibitor or 
CysLT1/ CysLT2 receptor antagonists significantly attenuated the increases in peak 
[Ca2+]i response evoked selectively by Ang II while the responses to other peptide 
agonists such as ET-1 and AVP in ASMC of both WKY and SHR strains.  The blockade 
was more pronounced in SHR, suggesting that the 5-LO-derived AA metabolites, CysLT, 
contribute to Ang II evoked exaggerated [Ca2+]i responses in SHR.  Secondly, LTD4 
evoked increases in [Ca2+]i was much higher than the responses evoked by LTC4.  These 
data confirmed the presence of CysLT1 and CysLT2 receptors on rat ASMC. Since the 
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responses to LTD4 was attenuated by Bay u9773, a dual CysLT antagonist, it was 
confirmed that LTD4 evoked responses may be mediated by activation of both CysLT1 
and CysLT2.  On the other hand, the weak [Ca
2+]i responses evoked by LTC4 remained 
unaffected in the presence of MK571 but were abolished by Bay u9773. This confirmed 
that LTC4  evoked responses may be linked to CysLT2 activation in ASMC in  either 
strain. The effects evoked by both LTD4 and LTC4 were more pronounced in SHR.  
Thirdly, The InSP3 antagonist, 2-APB, significantly reduced the [Ca
2+]i responses 
evoked by both Ang II and CysLTs, namely, LTC4 and LTD4.  Fourthly, the basal 
CysLT level in the culture medium of ASMC of SHR was significantly higher.  Ang II 
but not ET-1 led to an increase in CysLT generation in the ASMC of both strains.  The 
Emax values for Ang II were higher in SHR.  Fifthly, Ang II-evoked increases in both 
[Ca2+]i level and CysLT generation in ASMC of both WKY and SHR were mediated by 
AT1 and not AT2 subtype.  Finally, CysLT1/ CysLT2 receptor mRNAs were detected in 
ASMC of both strains and the expression levels of both subtypes were significantly 
higher in the SHR strain.  These data suggest that elevated CysLT production along with 
increased levels of CysLT receptors (both CysLT1 and CysLT2) may account for the 
exaggerated [Ca2+]i responses to Ang II in SHR and that this overactive pathway may 
contribute to exaggerated vasoconstrictor responses to Ang II in SHR due to increased 
mobilization of Ca2+ from InsP3 sensitive intracellular stores. 
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5.2.2   Exaggerated [Ca2+]i  Responses to ANG II, AVP and   ET-1 in ASMC of SHR 
In ASMC of WKY and SHR strains, the basal [Ca2+]i  levels observed in the present 
study in both normal (1.8 mM) and Ca2+ free buffer medium are consistent with previous 
studies (Batra et al., 1993; Touyz RM, 1997b).  The basal [Ca2+]i as well as the peak 
increases in [Ca2+]i evoked by agonists were lower in the Ca
2+
  free medium than the 
responses seen in normal Ca
2+
 medium and these data suggest that Ca2+ influx plays a 
role in Ang II-evoked responses (Batra et al., 1993; Touyz et al., 1997b). It has been 
proposed that the basal [Ca2+]i is higher in VSMC of SHR because of increased Ca
2+ 
influx through L-type voltage-dependent calcium channels (Touyz et al., 1997b).  Most 
importantly, the present study also demonstrates that, in both WKY and SHR, the Emax 
values for Ang II were much higher than that for AVP and ET-1. This is consistent with 
the suggestion that Ang II recruits multiple mechanisms in evoking its response.   
Moreover, the Emax values for Ang II, AVP and ET-1 were much higher in the ASMC of 
SHR than that in WKY.  These data are in line with the earlier studies (Batra et al., 1993; 
Touyz et al., 1997b).  Ang II mediates its effects on [Ca2+]i by InSP3-induced 
mobilization of Ca2+ from sarcoplamic reticulum, inducing a rapid and transient [Ca2+]i 
response initially, followed by influx through Ca2+ channels, resulting in a prolonged and 
sustained [Ca2+]i response (Dostal et al., 1990). Other studies showed that Ang II can 
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also cause calcium release from intracellular stores without involving the InsP3 receptor 
by a calcium-induced calcium-release mechanism (Morel et al., 1996). Although the 
activity of calcium channels is increased in hypertension, it has been proposed that an 
increase in Ca2+ influx is not a major mechanism that contributes to Ang II-evoked 
exaggerated [Ca2+]i  responses in VSMC from SHR (Touyz et al., 1997b). Instead, it is 
suggested that Ang II-induced exaggerated [Ca2+]i  response is dependent primarily on 
intracellular rather than extracellular mobilization of calcium. However, the exact 
mechanism underlying Ang II evoked exaggerated [Ca2+]i responses is still not fully 
understood.  
 
5.2.3   AT1 and AT2 subtypes on ASMC 
Both AT1 and AT2 receptor subtypes were expressed in VSMCs from WKY and SHR 
(El Mabrouk et al., 2001).   In the vasculature, AT1 receptors have been shown to 
mediate most of the physiological actions of Ang II, and this subtype is predominant in 
the control of Ang II-induced vascular functions (Sadoshima et al., 1998; Touyz et al., 
2000).  AT1 receptors are present at high levels in VSMC (Touyz et al., 2000; Allen et 
al., 2000). AT1 receptor has been linked to vascular remodeling because of its implication 
in vascular hypertrophy and/or hyperplasia, extracellular matrix deposition, and 
inflammatory responses (Matsusaka et al., 1997; Touyz et al., 2001).  In contrast, AT2 
receptor is expressed at very high levels in the fetus and its expression is very low in 
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adult VSMC (Nahmias et al., 1995; Touyz et al., 2001).  The physiological function of 
AT2 receptors has not been clearly defined, although several studies suggest that they 
have a proapoptotic effect on VSMC in normal rats (Cui et al., 2001; Suzuki et al., 2003; 
Kumar et al., 2004).  Other studies suggest that AT2 receptors play a role in 
differentiation and inflammation (Ruiz-Ortega et al., 2000; Yamada et al., 1999).  To 
date, studies have revealed controversial results concerning the role of AT2 receptor on 
VSMC growth in different rat models of experimental hypertension (Levy et al., 1996; 
Sabri et al., 1997; Cao et al., 1999; Otsuka et al., 1998). The exact role of AT2 receptors 
in the regulation of VSMC growth and in hypertension awaits further clarification.  The 
present study demonstrates that Ang II evoked increases in CysLT and [Ca2+]i levels 
were abolished by losartan but not by PD123319.  Therefore, AT1 receptor activation and 
the resultant PLC/InsP3 mediated [Ca
2+
]i responses may be partly mediated by AA-
derived CysLT production in ASMC.  These results support the view that AT1 receptor 
activation accounts for most or all of the vascular actions of Ang II. 
 
 
 
5.2.4   Cys LT Dependent [Ca2+]i  Responses to ANG II in ASMC     
Studies have demonstrated that Ang II-evoked vascular hypertrophy may be mediated by 
noncycloxygenase-derived AA metabolites (Dulin et al., 1998, Parmentier et al., 2001, 
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Zafari et al., 1999).  Recently, studies from our laboratories and by others have shown 
that 5-LO inhibitor or the CysLT1 antagonist reduced the vasoconstrictor responses to 
Ang II, suggesting that CysLT generation and subsequent CysLT1 receptor activation 
mediate vascular responses to Ang II (Shastri et al., 2001; Stanke-Labesque et al., 2001). 
Our study demonstrates that AT1 mediated CysLT generation and the subsequent CysLT 
evoked Ca2+ release from InsP3 sensitive intracellular stores could enhance direct Ang II 
evoked responses (Liu et al., 2003). Therefore, it is important to find direct evidence for a 
link between Ang II, AT1 receptor activation, CysLT generation and CysLT receptor 
mediated alterations in [Ca2+]i levels in ASMC. We have previously shown that Ang II 
evoked much greater increases in [Ca2+]i than either AVP or ET-1 in ASMC 
(Gopalakrishnan et al.,1991), though cell surface receptors for ET-1 are several orders of 
magnitude higher than the receptors for Ang II (Booz et al., 1996).  These data suggested 
that additional mechanisms and signal transduction events likely account for the much 
greater increases in [Ca2+]i responses to Ang II.  The present data confirms that Ang II 
increased CysLT generation via AT1 receptor activation. In contrast, neither 5-LO 
inhibitors nor CysLT1/ CysLT2 antagonists attenuated ET-1 evoked increases in [Ca
2+
]i 
levels and ET-1 failed to elicit CysLT generation, suggesting that only Ang II promotes 
CysLT production via AT1 receptor activation.  The present data shows that CysLT plays 
a more pronounced role in the exaggerated [Ca2+]i response to Ang II in SHR. In 
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addition, the present study demonstrates the consistency in time course response for the 
CysLT generation and the subsequent Ca2+ increase, suggesting that CysLT generation 
evoked by Ang II may serve as an additional amplifier pathway in sustaining direct AT1 
mediated Ca2+ mobilization in ASMC. This is consistent with the view that Ang II is a 
pleiotropic peptide that recruits multiple signaling pathways to account for its potential 
role in the regulation of cardiovascular function (Touyz et al., 2000). Thus, besides 
providing a possible explanation for the higher Emax to Ang II, the present study suggests 
for the first time that CysLT may play a more important role in Ang II–evoked 
exaggerated vasoconstriction/or vascular hypertrophy in SHR.   
 
5.2.5     CysLT and Ca
2+
 Signaling. 
 Studies have shown that CysLT signal through elevation of intracellular calcium by 
activation of CysLT1/ CysLT2 receptors (Lynch et al., 1999; Takasaki et al., 2000; Chan 
et al., 1994). In human detrusor smooth muscle cells, it was reported that elevation in 
[Ca2+]i levels evoked by LTD4 were almost exclusively due to mobilization from 
intracellular Ca2+ stores (Bouchelouche et al., 2001). In other target cells, the LTD4 
evoked Ca2+ response was dependent on the release of Ca2+ from intracellular stores and 
enhanced Ca2+ influx (Ochsner et al., 1996, Pedersen et al., 1997).  The present study 
demonstrates that CysLT evoked increase in [Ca2+]i may be mainly due to the release of 
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Ca
2+
 from InsP3 sensitive intracellular SR Ca
2+ pools in the ASMC. This is consistent 
with the data from other studies (Mazzetti et al., 2003; Bouchelouche et al, 2000).  
 
5.2.6   ANG II evoked CysLT generation in ASMC  
The present study has demonstrated for the first time that the basal CysLT level is higher 
in the ASMC of SHR and Ang II evoked more pronounced increase in CysLT generation 
in SHR.  This is the first report to provide the direct evidence for a link between Ang II 
and CysLT in ASMC.  Other studies have reported that Ang II elicits CysLT release from 
the aortic rings but they failed to monitor CysLT production in the ASMC (Stanke-
Labesque et al., 2001).  Besides higher basal CysLT level in SHR, the present data also 
show that both CysLT1 and CysLT2 receptor mRNA were detected in ASMC of both 
strains and the expression levels for both receptors were much higher in SHR. This seems 
to go against the rule that higher level of hormones usually lead to a down-regulation of 
their receptors via a physiological negative feedback mechanism. However, studies 
dealing with Ang II, ET-1 and AVP have reported up-regulation of their receptors 
irrespective of their elevated levels in cardiovascular disease states (Cheng et al., 1995; 
Peng et al., 2002; Okamura et al., 1999; Shibataet al., 1997, Wagner et al., 1998; 
Tonnessen et al., 1997; Kobayashi et al., 1999).  More particularly, it has been shown that 
Ang II upregulates AT1 receptors in renal proximal tubules (Cheng et al., 1995). Other 
studies have demonstrated that both Ang II and AT1 receptor levels are simultaneously 
elevated (Peng et al., 2002; Okamura et al., 1999; Shibata et al. 1997, Wagner et al., 
1998). Similarly, it has been reported that the ET-1 peptide level, the ETA- and ETB-
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receptor expression are upregulated in the heart of rats with chronic heart failure 
(Kobayashi et al., 1999; Tonnessen et al., 1997).  All these studies support our present 
observation. The reason for the higher basal CysLT level and receptor expression could 
be attributed to the higher plasma Ang II level and overactive AT1 activation that may 
enhance both 5-LO-mediated CysLT generation of CysLT-R expression in SHR.  On the 
other hand, it is also possible that the up-regulated CysLT system serves as an additional 
amplifier pathway for the exaggerated [Ca2+]i responses to Ang II and finally leads to the 
generation of hypertension and vascular hypertrophy in SHR. 
  
5.2.7 Cys LT Receptors in ASMC 
Human CysLT1 and CysLT2 receptors have been cloned and characterized only in  recent 
years (Heise et al., 2000; Lynch et al., 1999). Several recent studies have proposed the 
presence of CysLT1 and CysLT2 transcripts in cardiac and vascular tissues (Heise et al., 
2000; Kamohara et al., 2001; Lynch et al., 1999; Ogasawara et al., 2002).  The present 
data have demonstrated for the first time that both CysLT1 and CysLT2 receptor are 
expressed in ASMC. Consistent with this observation, we have further noted that both 
LTD4 (MK571 sensitive) and LTC4 (MK571 resistant) evoke concentration-dependent 
[Ca2+]i responses in ASMC. Moreover, Bay u9773 completely blocked both LTD4 and 
LTC4 evoked [Ca
2+]i responses, confirming that ASMC possess both CysLT1 and 
CysLT2 specific binding sites that are linked to Ca
2+ mobilization.  Previously, it was 
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reported that the affinity of LTC4 for CysLT1 receptor was roughly 10 to 350 fold lower 
than that of LTD4 (Heise et al., 2000; Lynch et al., 1999).  Overall, the rank order of 
affinities of the CysLT for the CysLT1R and CysLT2R is LTD4>>LTC4>LTE4 and 
LTD4=LTC4>>LTE4 respectively (Heise et al., 2000, Maekawa et al., 2002). In the 
present study, LTD4 evoked stronger response than LTC4 did in either WKY or SHR, 
further suggesting that LTD4 exert its effects via activation of both CysLT1 receptor and 
CysLT2 receptor while LTC4 mediate its effects predominantly via activation of CysLT2 
receptor. These results are in line with the earlier findings (Aharony, 1998; Heise et al., 
2000; Lynch et al., 1999; Maekawa et al., 2002; Ogasawara et al., 2002).  
 
In conclusion, the present study confirms that elevated CysLT production along with 
increased levels of CysLT receptors (both CysLT1 and CysLT2) may account in for part 
the exaggerated [Ca2+]i responses to Ang II in SHR via mobilization of Ca
2+ from InsP3 
sensitive intracellular stores. As it has been suggested that the elevation in [Ca2+]i level 
play a more critical role than PKC activation towards hypertrophy evoked by Ang II 
(Sadoshima et al., 1993,1995 a & b),  taken together with our new findings, these data 
provide the impetus for a more detailed characterization of the interactions between Ang 
II, CysLT generation and CysLT receptor mediated increase in Ca2+ mobilization and 
their relative roles and contribution to vascular hypertrophy and hypertension. 
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6.  SUMMARY OF FINDINGS AND CONCLUSIONS 
6.1  For  Neonatal Rat  Cardiomyocyte 
1. Ang II, AVP and ET-1 evoked concentration-dependent increases in [Ca
2+
]i levels in 
NRC.  The Emax values for Ang II were much higher than that for AVP and ET-1.  
 2. Ang II evoked time- and concentration-dependent increases in CysLT production in 
NRC.  Ang II evoked increases in [Ca
2+
]i levels and CysLT production were mediated 
by AT1 but not AT2 receptors. 
3.  Inclusion of the 5-LO inhibitor or the FLAP inhibitor, or CysLT receptor antagonists, 
led to significant reduction in Ang II but not AVP or ET-1 evoked increases in [Ca
2+
]i 
levels.  Therefore, CysLTs may partially contribute to Ang II-evoked increase in [Ca2+]i 
in NRC 
4. Both CysLT1 and CysLT2 receptor mRNA were detected in NRC. 
5. Both LTD4 and LTC4 evoke concentration-dependent increases in [Ca
2+
]i in NRC. 
Moreover, the CysLT1 selective antagonist, MK571, blocked LTD4 but not LTC4 evoked 
increases in [Ca
2+
]i levels while the dual CysLT1 / CysLT2 receptor antagonist, Bay 
u9773, abolished the [Ca
2+
]i responses to both LTD4 and LTC4, suggesting that LTD4 
evoked responses are mediated by both CysLT1 and CysLT2 receptors, while LTC4 
predominantly activate CysLT2 receptors present on NRC. 
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6. Both Ang II and CysLTs evoked increases in [Ca
2+
]i were markedly attenuated by 2-
APB suggesting that CysLTs recruit predominantly InsP3 sensitive intracellular Ca
2+ 
pools in NRC. Therefore, the CysLT pathway may serve as an additional amplifier 
pathway in sustaining direct AT1 mediated Ca
2+ signaling evoked by Ang II in NRC.  
 
6.2  For  VSMC 
1. Ang II, AVP and ET-1 evoked concentration increases in [Ca
2+
]i levels in ASMC 
from both WKY and SHR.  The Emax values for all these peptides were higher in SHR 
than that in WKY.  Most importantly, The Emax values for Ang II were much higher than 
that for AVP and ET-1.  
2. In both WKY and SHR, either AA861, or MK591, or MK571, or Bay u9773 led to 
significant reduction in Ang II but neither AVP nor ET-1 evoked increases in [Ca
2+
]i in 
both normal and Ca2+ free buffer. Also, AT1 but not AT2 receptor antagonists 
completely blocked Ang II-evoked increase in [Ca
2+
]i levels. 
 
3. The basal CysLT level is much higher in SHR than that in WKY. Ang II but not AVP 
or ET-1 evoked time- and concentration- dependent increases in CysLT generation in the 
culture medium of ASMC from both WKY and SHR. The Emax values for Ang II were 
much higher in SHR than that in WKY. AT1 but not AT2 receptor antagonist completely 
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blocked Ang II-evoked increase in CysLT level.  Both 5-LO inhibitor and FLAP inhibitor 
also abolished Ang II-evoked response. The blockade effects were more profound in 
SHR, suggesting that CysLTs may play a role in Ang II-evoked exaggerated 
vasoconstrictor responses seen in SHR strain. 
4. LTD4 and LTC4 evoked concentration-dependent increases in [Ca
2+
]i levels in ASMC 
from both WKY and SHR in both normal and Ca2+ free buffer.  Similar Emax values 
were obtained for either LTD4 or LTC4 in both normal and Ca2+ free buffer. LTD4 
evoked stronger responses than LTC4. Most importantly, both LTD4 and LTC4 evoked 
much greater increases in [Ca
2+
]i levels in ASMC of SHR than the responses noted in 
ASMC of WKY strain.  
5. In both WKY and SHR, the CysLT1 selective antagonist, MK571, partially blocked 
LTD4 but not LTC4 evoked increases in [Ca
2+
]i levels while the dual CysLT1/CysLT2 
receptor antagonist, Bay u9773, abolished the [Ca
2+
]i responses to both LTD4 and LTC4, 
suggesting that LTD4 evoked responses was mediated by activation of both CysLT1 and 
CysLT2 receptor, while LTC4 predominantly activate CysLT2 recetopr, resulting in 
elevated  [Ca
2+
]i in ASMC. 
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6. Ang II evoked increases in [Ca
2+
]i were markedly attenuated by 2-APB. While CysLT 
evoked increases in [Ca
2+
]i were abolished by 2-APB, suggesting that CysLT recruit 
predominantly InsP3 sensitive intracellular Ca
2+ pools in ASMC. 
7. Both CysLT1 and CysLT2 receptor mRNA were detected in ASMC from both WKY 
and SHR. However, the CysLT1 and CysLT2 receptor mRNA levels were much higher in 
SHR than that in WKY. 
 
Therefore, the CysLT pathway may serve as an additional amplifier pathway in 
sustaining direct AT1 mediated Ca
2+ signaling evoked by Ang II in ASMC. This 
pathway could be more important in the exaggerated vasoconstrictor responses to Ang II 
in the SHR. 
 
A schematic diagram elucidating the signal transduction for AT1 receptor interation with 
the CysLT system and its role in Ca2+ mobilization in NRC and ASMC is presented in  
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7    Future Directions 
1.  To study the distribution of CysLT1/CysLT2 specific binding sites on NRC and 
ASMC.  Although CysLT1/CysLT2 receptor mRNA was detected by northern blot 
analysis in the present study, radioligand binding studies would provide more detailed 
characteristics such as the affinity and the site density of the CysLT receptors present in 
the cardiovascular tissues.  This would provide more direct evidence in support of the 
expression data repoted in the present study.   
2.  To study the CysLT1/CysLT2 receptor protein expression in NRC & ASMC. It would 
be more convincing if the receptor proteins could be directly detected by western blot 
Analysis. 
3. To study the involvement and contribution of CysLT in Ang II evoked cardiovascular 
hypertrophy and the role of increased [Ca2+]i in the systhesis of DNA and protein. 
Although studies have suggested that increase in [Ca2+]i plays an important role in 
mediating  cardiac and vascular hypertrophy,  further study to eluciate the direct effects 
of CysLT on the systhesis of  DNA and protein is important for concluding that CysLT 
contributes to Ang II evoked cardiovascular hypertrophy. 
4. To study the effect of PLA2 inhibitor on the Ang II evoked increases in Ca
2+ and 
CysLT production.  PLA2 is a key enzyme in mediating AA release. Employing a  
selective PLA2 inhibitor would provide further supportive evidence for the contribution 
of CysLT to Ang II evoked Ca2+ signaling in both NRC and ASMC. 
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